Search this site

SleepTech Market Projections 2026 Executive Summary: The SleepTech Inflection Point (2026 Strategic Overview) The global sleep technology sector is poised for a significant strategic inflection point by 2026, driven by the convergence of advanced consumer hardware and clinically validated digital therapeutics. Market forecasts confirm a robust growth trajectory, positioning the sector to move decisively beyond generalised wellness tracking into the regulated realm of personalised health intervention. The global Sleep Tech Devices market is projected to reach approximately USD $30.74 Billion to USD $32.00 Billion in 2026. This high valuation is supported by aggressive long-term growth forecasts, with Compound Annual Growth Rates (CAGRs) projected to range from 15.5% (2026-2035) to 18.5% (2025-2034). A defining strategic shift is the integration of Artificial Intelligence (AI) and machine learning, transforming the market from passive data collection to active, prescriptive therapy. Leading innovators are making significant capital commitments to developing sophisticated AI roadmaps, including the use of large language models (LLMs) to create predictive "digital twins" that proactively adjust the sleep environment. This technological leap establishes a strong competitive advantage built on outcome delivery rather than mere data provision. Furthermore, the sector has achieved a crucial step toward clinical credibility through regulatory validation. The FDA clearance of Prescription Digital Therapeutics (PDTs) for chronic insomnia, such as SleepioRx and Somryst, is establishing clear, reimbursable clinical pathways. This regulatory progress is essential for accessing the massive high-value healthcare market. Geographically, North America currently holds the largest share, but the Asia Pacific region is anticipated to be the fastest-growing market, demanding tailored strategies focusing on accessibility and government digital health integration. Global SleepTech Market Dynamics and 2026 Projections A. Market Size Reconciliation and Growth Trajectory (2025–2035) The SleepTech industry’s expansion trajectory remains exceptionally strong, buoyed by chronic health challenges and continuous technological advancement. Analysis of multiple forecasts confirms a 2026 market size exceeding USD $30 Billion. Specifically, Research Nester projects the market size to reach USD $30.74 Billion in 2026, supporting a long-term CAGR of 15.5% through 2035, resulting in a forecasted valuation of USD $113.99 Billion. Global Market Insights corroborates this outlook, projecting revenue will surpass USD $32 Billion by 2026. More aggressive forecasts anticipate even higher growth. Precedence Research, for example, projects an 18.46% CAGR from 2025 to 2034, leading to a market valuation of approximately USD $134.60 billion by 2034. This notable divergence in long-term CAGR, ranging from 15.5% to 18.5% is likely attributable to differing assumptions regarding the pace of clinical integration and reimbursement expansion. Higher projections anticipate a more successful and rapid navigation of regulatory hurdles and subsequent uptake of high-value, medical-grade devices and Prescription Digital Therapeutics (PDTs). The successful transition of a large portion of the current consumer market into a clinical, insurance-reimbursable pathway would provide the structural financial impetus necessary to sustain growth at the higher end of the forecasted range. The underlying growth is robustly supported by fundamental market drivers, including the rising global prevalence of chronic sleep disorders (insomnia, sleep apnea, restless leg syndrome) and a heightened global awareness of sleep health’s impact on overall well-being in the post-pandemic era. Global Sleep Tech Devices Market Projections (2026-2035) Source Base Year Market Size (USD Bn) 2026 Projected Size (USD Bn) Forecast Period Projected CAGR Long-Term Forecast (USD Bn) Research Nester 2025 (26.98) 30.74 2026-2035 15.5% 113.99 (by 2035) Precedence Research 2024 (24.85) N/A 2025-2034 18.46% 134.60 (by 2034) Global Market Insights N/A > 32.00 2020-2026 16.6% (Through 2026) N/A SNS Insider 2025 (27.46) N/A 2026-2033 17.96% 102.76 (by 2033) B. Core Market Segmentation Analysis: Product and Application Product Dominance and Emerging Segments The market remains heavily skewed toward the Wearables segment, which includes smartwatches, fitness trackers, and specialized smart rings. This segment held the largest share, approximately 75.7%, in 2024 and is expected to retain its dominance throughout the forecast period. The market for wearable sleep-tracking devices alone is projected to reach USD $7 Billion by 2026. This sustained growth is driven by the accessibility and popularity of integrated health monitoring features, including SpO2​ and heart rate tracking, in daily-use consumer devices. However, significant strategic interest is growing in the Non-Wearables segment. This category, encompassing smart bedding, adjustable bases, and non-contact bedside sensors (such as Wakefit’s Track8) , is driven by consumer preference for monitoring solutions used within the residential setting. The residential end-user segment is the largest market consumer, and the preference for at-home solutions (reported by 75% of consumers) validates the increasing clinical shift toward Home Sleep Apnea Testing (HSAT), which has seen remarkable growth of 45% annually since 2020. This trend is fundamentally reducing the dependency on expensive, centralized Polysomnography (PSG) labs. Application Focus and the SaMD Opportunity By application, insomnia dominates the market, capturing approximately 47.9% of the revenue share in 2024. This high concentration of demand creates a unique and high-margin opportunity for software innovation. The successful clinical validation and FDA clearance of dCBT-I (a software solution) confirms the viability of the Software-as-a-Medical-Device (SaMD) segment. This pathway allows companies to capture significant revenue from a dominant application without the complexity and capital expenditure required for traditional medical hardware manufacturing. The Sleep Apnea application remains essential, with demand for specialized devices and related replacement supplies (e.g., CPAP) expected to increase, particularly in high-prevalence areas like the United States and China. HealthTech Innovation: The Transformation from Tracking to Therapy A. The AI-Powered Sleep Revolution and Personalised Interventions The SleepTech industry’s evolution is characterised by a definitive move toward using Artificial Intelligence to provide sophisticated, prescriptive intervention, transforming the function of devices from passive tracking to active therapeutic support. Predictive Analytics and Digital Twin Technology The most ambitious technological advancements center on developing highly personalized, closed-loop systems. This is exemplified by major capital injections such as the $100 million secured by Eight Sleep, explicitly to fund AI roadmaps. These roadmaps involve applying large language models (LLMs) to human physiological data to create "digital twins." By simulating thousands of possible outcomes, the AI can precisely predict the user's optimal recovery needs and proactively adjust the sleep environment (e.g., controlling mattress temperature or elevation). This technological complexity moves beyond basic algorithms, creating a competitive distinction where the value lies in delivering a guaranteed outcome rather than simply displaying raw biometric data. Personalisation is increasingly sophisticated, with devices like the Oura Ring providing a comprehensive Sleep Score based on body signals such as core temperature, heart rate, and sleep stage duration. The corresponding app offers individualised guidance to optimise recovery and daily performance. Similarly, Samsung is integrating advanced sleep monitoring throush its Health SDK to promote personalised, preventive health management. AI in Clinical Workflow and Adherence AI is proving vital in addressing critical bottlenecks in clinical sleep medicine, particularly patient non-adherence to established treatments. High non-adherence rates (29%–83%) plague Continuous Positive Airway Pressure (PAP) therapy for Obstructive Sleep Apnea (OSA). AI addresses this by developing algorithms that predict non-adherence risk using a combination of patient health characteristics, clinical scores (like the STOP-BANG score), and even subtle physiological indicators, such as specific patterns in lipid profiles. This predictive capability allows clinicians to receive early alerts and intervene proactively, improving the overall success rate of complex treatment regimens. B. The Era of Advanced Sensing and Non-Contact Monitoring The demand for high-fidelity data collection without compromising user comfort or compliance is driving the adoption of advanced sensing techniques. Migration to Clinical-Grade Biosensors By 2026, the market is expected to witness a definitive shift toward high-precision, medical-grade biosensors, moving beyond standard consumer-grade wearables. These advanced sensors facilitate non-invasive, quantitative assessment of vital parameters, including heart rate variability (HRV), SpO2​ levels, and respiratory analysis. This enhanced data accuracy is essential for transforming sleep monitoring from a wellness tool into a reliable diagnostic aid used in both remote monitoring and clinical settings. Non-Contact Solutions and Improved Compliance Non-contact technology, including advanced smart beds and under-mattress sensors, plays a crucial role in improving long-term compliance by eliminating the need for the user to wear a device. Continuous passive monitoring enables the collection of uninterrupted, long-term data sets necessary for diagnosing and managing chronic conditions. The popularity of smart home integration, as seen with Google Nest's sleep ecosystem, further reinforces the importance of non-contact, residential solutions. Regulatory and Clinical Integration: Bridging the Gap (2026 Mandate) A. The Critical Role of Prescription Digital Therapeutics (PDTs) The widespread prevalence of chronic insomnia necessitates accessible, evidence-based treatments. Cognitive Behavioural Therapy for Insomnia (CBT-I) is the recommended standard of care. The successful regulatory clearance of digital therapeutics is transforming how this care is delivered. FDA Clearances and Efficacy The FDA clearance of dCBT-I solutions marks a paradigm shift. Big Health's SleepioRx received FDA clearance in August 2024 for chronic insomnia as an adjunct to usual care. This product, intended as a 90-day treatment, is based on cognitive-behavioral techniques and has been validated in over 25 clinical trials. Similarly, Somryst is an FDA-authorised prescription digital therapeutic delivering mobile-based CBT-I. Clinical studies confirm the efficacy and far-reaching benefits of these PDTs. A prospective study evaluating Somryst demonstrated a clinically meaningful reduction in the Insomnia Severity Index (ISI) scores (a drop from 18.8 to 9.9 for engaged users), with benefits sustained up to one year after treatment completion. A key finding is the simultaneous and significant reduction in symptoms of co-occurring depression (PHQ-8) and anxiety (GAD-7). This evidence confirms that effective digital sleep therapeutics provide holistic benefits, positioning them as essential entry points into the broader digital mental healthcare market. Favourable Coverage Trends Regulatory bodies and payers are increasingly supporting cost-effective, remote diagnostic tools. Coverage expansions by Medicare and Medicaid for Home Sleep Apnea Testing (HSAT) devices demonstrate regulatory acceptance of remote diagnostics. For instance, Medicare typically covers 80% of the cost for medically necessary HSAT after the deductible is met, and Continuous Positive Airway Pressure (CPAP) devices are covered as Durable Medical Equipment (DME). These reimbursement mechanisms pave the way for other FDA-cleared sleep-monitoring and therapeutic devices to achieve widespread clinical adoption and patient access. B. Regulatory Headwinds and Clinical Adoption Barriers Despite progress in the PDT segment, the broader integration of consumer devices into clinical practice faces persistent regulatory and scientific challenges. Regulatory Complexity and Validation A key hurdle is the regulatory ambiguity distinguishing consumer wellness devices from medical devices. Consumer devices often rely on proprietary algorithms that are not disclosed or validated through rigorous, comparative clinical trials, hindering their acceptance by healthcare reimbursement systems. Regulatory agencies require extensive validation studies for medical claims, leading to prolonged approval processes that slow the commercialization of cutting-edge innovation. Need for Standardisation Clinical adoption is further restrained by the lack of standardised guidelines for evaluating the performance of consumer-grade sleep trackers. Clinicians face difficulties interpreting data generated by devices with varying proprietary algorithms and frequent firmware updates. Although the American Academy of Sleep Medicine (AASM) recognises the surging utilisation of consumer devices and encourages clinicians to be familiar with patient-generated health data , full clinical integration requires a careful path forward involving clear guidelines for reliability and data integrity. Key FDA-Cleared Digital Therapeutics and Clinical Adoption Status Digital Therapeutic / Device Indication Regulatory Status Clinical Efficacy Highlight Strategic Implication for 2026 SleepioRx (Big Health) Chronic Insomnia FDA-Cleared (Aug 2024) Efficacy in chronic sleep issues across 25+ trials. Significant reduction in insomnia severity, depression, and anxiety. Establishes reimbursable pathway for software-only treatments; critical benchmark for dCBT-I segment. Somryst (Pear Therapeutics) Chronic Insomnia FDA-Authorized Clinically meaningful improvements in Insomnia Severity Index (ISI) scores, sustained for 1 year. Confirms long-term adherence and effectiveness of mobile-delivered CBT-I. Home Sleep Apnea Testing (HSAT) Devices Obstructive Sleep Apnea (OSA) Diagnosis CMS/Payer Coverage Expanding Cost-effective alternative to PSG; 45% annual growth since 2020. Drives the shift to residential/at-home diagnostics; lowers patient entry barrier due to high insurance coverage. Regional Strategic Outlook and Competitive Landscape A. Geographic Growth Vectors (2026–2035) The global market presents a bifurcated strategic landscape defined by distinct regional growth dynamics. North America: Market Leadership and Premiumisation North America is projected to retain its status as the region with the largest overall market share, encompassing 42.6% in 2024. Its growth is supported by a confluence of factors: high prevalence of sleep disorders, robust R&D investment, and consumer willingness to adopt high-cost, premium solutions. The concentration of major market players and frequent product launches ensures the region remains the primary incubator for high-specification clinical technology. The high entry cost for premium devices (ranging from $500 to $5,000) implies the North American strategy must prioritise clinical validation and sophisticated AI integration to justify premium pricing and maximise access to private insurance and government reimbursement. Asia Pacific: The Fastest Growth Engine The Asia Pacific region is anticipated to achieve the most aggressive CAGR (e.g., 17.5% through 2026). This expansion is fueled by rapidly increasing health awareness, supportive government initiatives (such as India's National Digital Health Mission incorporating monitoring tools) , and rising incidence rates of stress-related conditions like depression and anxiety. This market requires a high-volume, cost-effective strategy, where local players like Xiaomi and Huawei offer accessible monitoring solutions tailored to the regional economic landscape. B. Competitive Dynamics and Investment Focus The market is currently semi-consolidated, featuring strong competition among diversified actors. Leading players include specialized sleep firms (Eight Sleep, Oura Health), traditional MedTech (Koninklijke Philips N.V., Compumedics), and consumer electronics giants. Investment Trends: AI and Medical Expansion Recent major investment rounds reflect a clear strategic focus on technological differentiation and medical expansion. Eight Sleep’s $100 Million funding round in 2025 specifically targeted its AI roadmap and entry into the medical sector, aiming for FDA approval for certain sleep applications, beginning with menopausal sleep and sleep apnea. This significant capital injection underscores the market’s realization that proprietary AI capabilities, such as digital twin simulation, are essential for establishing a durable competitive moat and justifying the investment required to navigate the high-barrier regulatory pathway. The competitive landscape is bifurcating: one segment focuses on the development of complex, regulated medical devices and SaMD solutions to maximise revenue through reimbursement, while the other focuses on delivering affordable, advanced consumer devices for massive scale, particularly in emerging Asian markets. Success hinges on a clear decision regarding which segment to target, or the effective management of a dual-market product strategy. Conclusions and Strategic Recommendations The SleepTech sector is entering a period of profound transformation where software intelligence and clinical validation supersede basic hardware tracking. The market will exceed $30 billion by 2026, driven by sustained demand for effective solutions to chronic sleep disorders and fueled by breakthroughs in AI and digital therapeutics. Strategic Recommendations Mandate Clinical Validation for High-Value Applications: HealthTech firms must aggressively pursue FDA clearance (or equivalent international certification) for specific, high-prevalence applications, such as chronic insomnia (via dCBT-I) and continuous sleep apnea monitoring. Following the regulatory precedents set by SleepioRx and Somryst, this transition from the consumer wellness category to a regulated medical device or therapeutic is the single most critical action to unlock insurance reimbursement and high-margin revenue streams. Centralize Product Development Around AI-Driven Outcomes: Future investment must prioritize the shift from simple tracking to predictive, prescriptive intervention. Developing advanced capabilities like digital twins and large language model-powered coaching agents is necessary to translate complex physiological data into actionable, personalized adjustments to the sleep environment or behavioral regimens. This technology ensures the system delivers verifiable outcomes, establishing a competitive edge over commoditized tracking devices. Establish Partnerships for Standardisation and Clinical Integration: To accelerate the adoption of consumer-generated data in clinical settings, companies should collaborate directly with professional organisations like the AASM and key research institutions. These partnerships are necessary to standardize measurement algorithms and validate consumer device accuracy against clinical gold standards. This collaboration is crucial for training clinicians and securing regulatory acceptance for remote diagnostic and monitoring reimbursement models. Adopt a Geo-Specific Strategy: Capital allocation should reflect the regional dichotomy: focus on delivering high-cost, medically certified, AI-powered solutions to the North American market, leveraging the established regulatory and reimbursement structure. Simultaneously, develop scalable, cost-effective, digitally integrated solutions tailored for rapid adoption and volume growth within the Asia Pacific market, capitalising on government digital health initiatives. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Navigating the AI Correction: Assessing the Contagion Risk and Strategic Impact of the Bank of England’s Tech Bubble Alarm on HealthTech Valuations and Investment Executive Summary: The Financial Policy Committee (FPC) Mandate and HealthTech’s Exposure The global financial system is currently operating under a pervasive and quantifiable risk of a sharp market correction, a hazard explicitly documented by the Bank of England's (BoE) Financial Policy Committee (FPC) in its October 2025 update. The core driver of this instability is the hyper-concentration and seemingly limitless valuation of assets tethered to Artificial Intelligence (AI) technology. The FPC has raised a clear warning regarding the growing risk that tech stock prices, inflated by the AI boom, could burst. A. Thesis Statement The official assessment confirms that "equity market valuations appear stretched, particularly for technology companies focused on artificial intelligence". This speculative fervor mirrors previous bubbles and introduces systemic financial risk, which is highly transmissible to global markets, including the United Kingdom’s financial system. Within the HealthTech sector, AI has commanded a significant valuation premium, with AI-enabled startups achieving an 83% higher average deal size compared to their non-AI counterparts. However, a systemic market correction will inevitably test the viability of these valuations. The capital freeze resulting from a macro-shock will disproportionately affect non-validated, speculative business models, particularly those reliant on substantial, long-term venture capital runways, such as AI Drug Discovery (AIDD), which must navigate complex, multi-year clinical and regulatory approval pathways. B. Projected Scenarios for the HealthTech Sector The market faces two primary trajectories following the BoE’s alarm: Hard Landing: This scenario envisions a severe downturn comparable to the dot-com bust of 25 years ago. This outcome would be triggered by a confluence of waning investor optimism regarding AI’s immediate impact and a potential political or monetary stability shock (such as a loss of confidence in the U.S. Federal Reserve’s credibility). Such an event would result in "finance drying up" instantly for households and businesses, annihilating speculative valuations and reordering the entire tech landscape. Soft Landing/Segmentation: A more gradual normalization of valuations, where the correction primarily affects generalized AI foundation models. HealthTech’s destiny in this scenario is bifurcated: Administrative AI tools that demonstrate clear, rapid Return on Investment (ROI) and operational efficiency show resilience, while high-burn, long-horizon research sectors like AIDD face steep and immediate valuation haircuts until they can generate tangible clinical proof points. C. Critical Action Mandate In anticipation of this volatility, the critical mandate for institutional investors is to fundamentally pivot diligence away from mere technological capability and toward demonstrable clinical validation, verifiable commercial viability, superior capital efficiency, and proprietary data moats. For HealthTech operators, the focus must shift to fortifying runways, enhancing operational compliance, and integrating solutions deeply into physician workflow to ensure contract stickiness irrespective of market conditions. The following table summarises the macro-financial indicators that underpin the BoE’s current assessment. Key Indicators of Global AI Market Overvaluation (Q4 2025) Indicator BoE/Analyst Assessment Historical Context/Implication Stock Market Concentration (S&P 500 Tech Weight) ≈ 30%-40% of S&P 500 Value Highest concentration in over half a century; amplifies systemic risk Risk Premia Levels Compressed relative to historical distributions Prices do not adequately account for downside risk, signaling complacency CAPE Ratio (Shiller P/E) Exceeding 30 in major tech segments Historically correlates with bubble territory (e.g., Great Depression, 2000 Dot-com) Valuation Trajectory Equity valuations appear "stretched," comparable to the late 1990s dot-com boom Signals potential for sharp, aggressive repricing The Macro-Financial Stability Warning: Deconstructing the Bank of England’s Alarm A. The FPC’s October 2025 Assessment: Stretched Valuations and Correction Risk The Bank of England’s Financial Policy Committee, tasked with safeguarding financial stability across the UK, issued a pointed warning on Wednesday, October 8, 2025, regarding the state of global equity markets. The central bank explicitly flagged the potential for tech stock prices, which have been significantly "pumped up by the AI boom," to suddenly burst.The official determination was clear: "The risk of a sharp market correction has increased," based on the observation that "equity market valuations appear stretched, particularly for technology companies focused on artificial intelligence". This environment has been likened by analysts to the "dizzying heights seen during the dot-com bubble of 25 years ago," underscoring the peril inherent in speculative fervor. Jamie Dimon, a prominent voice in financial markets, conceded that a portion of the vast sums currently invested in AI would "probably be lost," suggesting an inevitable pruning of non-viable ventures. A fundamental concern articulated by the BoE is the extreme level of systemic concentration risk. Share prices for major technology firms, including giants such as Nvidia, Microsoft, Apple, Alphabet, Amazon, and Meta, now constitute approximately 30% of the S&P 500's total value. Some economic analyses place the aggregate weighting of tech stocks closer to 40% of the S&P 500. This high level of concentration has not been witnessed in over half a century, leaving equity markets acutely vulnerable "should expectations around the impact of AI become less optimistic". B. Quantitative Indicators of Hyper-Valuation and Financial Instability Market analysts support the central bank's warning by pointing to key quantitative indicators of excessive optimism. Symptoms cited include the rapid, unmoored growth in tech stock prices, valuations that are "stretched" beyond their fundamental underlying worth, and a "general sense of extreme optimism" despite the enormous uncertainties surrounding the ultimate yield of this technology. Historical metrics, such as Shiller's Cyclically Adjusted Price-to-Earnings (CAPE) ratio, serve as a potent warning; markets where this ratio exceeds 30 have historically been categorized as bubble territory, preceding major events like the Great Depression and the 2000 dot-com crash. Furthermore, the FPC observed that risk premia across a range of risky asset classes are compressed relative to their historical distributions. This indicates widespread investor complacency, where current asset prices fail to adequately account for potential downside risks. The BoE also identified specific non-financial downside risks that could crystallise and trigger a sudden correction, including shortages in critical inputs such as electricity, essential data, or advanced chips, or technological shifts that diminish the need for the currently dominant AI infrastructure. C. The Compounded Contagion Risk and Structural Dependencies The risks facing the market are not merely isolated to AI valuations; they are compounded by macroeconomic vulnerabilities. The BoE explicitly connected the AI bubble risk to threats concerning the political and operational credibility of the U.S. Federal Reserve. The FPC cautioned that "a sudden or significant change in perceptions of Federal Reserve credibility could result in a sharp repricing of U.S. dollar assets," potentially impacting sovereign debt markets and increasing global borrowing costs. This interdependency means that a domestic US market correction, driven by AI valuation decompression, when combined with a potential US monetary or political stability shock, creates a severe double-leveraged risk factor. For HealthTech ventures, this implies that valuation decompression is not simply an internal consequence of failure to deliver product, but an immediate external credit shock, ensuring that private finance, particularly for high-risk development ventures, will instantly and materially contract. This systemic fragility is exacerbated by the reliance on a handful of mega-cap technology companies. While the major players driving AI development are established and diversified, a crucial difference from the 2000 bubble , the sheer concentration of capital in these "Magnificent Seven" and large foundation model players means that any significant correction in their stock, even if they remain fundamentally solvent, triggers a much broader equity market downturn. This structural dependency ensures that the HealthTech ecosystem, which relies on the overall health of the VC-backed IPO environment for successful exits, faces an amplified systemic risk from the financial performance of the AI giants. A liquidity freeze stemming from a general market decline will severely impair exit opportunities and cripple the late-stage fundraising pipelines essential for HealthTech growth. The AI Hype Cycle and Lessons from Prior Tech Corrections A. Historical Analogs: Dot-com vs. Digital Health 1.0 (2021) The current market environment, characterised by intense investor focus on technical metrics over traditional financial fundamentals and the introduction of new valuation methodologies, strikingly follows classic historical bubble patterns.Market narratives inherently fuel bubbles and crashes, necessitating extreme caution for long-horizon investors. The HealthTech sector itself offers a recent, relevant precedent: the 2021 Digital Health correction. Following the peak of pandemic-era funding exuberance, the sector experienced a steep market correction. By 2024, total cash raised by healthcare startups had fallen by 58% compared to the 2021 annual total, while the overall deal count was down 32%.This sudden reversal left a cohort of later-stage companies that had received "lofty valuations" during the hype cycle caught in a debilitating "valuation trap". Success in the subsequent recovery phase has been defined by a new, higher bar, demanding "clearer paths to profitability, more efficient growth, and a differentiated path to value creation". B. Capital Flow Dynamics and Concentration of Risk (2024-2025) The enthusiasm around AI translated into explosive capital growth. The year 2024 marked a breakout period for AI funding, reaching over $100 billion, an increase of more than 80% year-over-year from 2023. This aggressive funding trajectory continued into 2025, driven heavily by massive megarounds. The structure of this funding reflects the highly concentrated macro risk identified by the BoE. In Q3 2025, capital concentration reached historic highs: $45 billion, or approximately 46% of global venture funding, was directed to the AI sector. Crucially, over 30% of all venture funding was concentrated into just 18 megarounds of $500 million or more, overwhelmingly allocated to foundational AI model companies like Anthropic, xAI, and Mistral AI. This macro trend has defined HealthTech investment. AI has progressed from a desirable feature to a strategic imperative in healthcare. As a result, AI-focused companies captured 62% of all HealthTech venture capital dollars in the first half of 2025. C. The Contradiction in HealthTech Funding and Temporal Mismatch An examination of HealthTech capital flows reveals a critical contradiction: while the sector is attracting substantial interest, the overall investment landscape remains highly selective. Digital health venture funding reached $6.4 billion in the first half of 2025, up slightly from $6.0 billion in H1 2024, signaling resilience. However, the number of deals (245) represents the lowest potential annual total since 2020 if the pace continues. Simultaneously, the average deal size has surged to $26.1 million in H1 2025, an increase from $20.4 million in 2024. This pattern confirms an aggressive market filter: investment is flowing, but only into established, later-stage AI players perceived as frontrunners. While this selectivity suggests prudence, the rising median deal sizes, particularly in Series B and D rounds , inflate the current cohort, potentially setting them up for a 'second wave' valuation trap akin to the post-2021 vintage. Furthermore, a significant temporal mismatch exists between investor expectations and clinical reality. General Partners (GPs) face mounting pressure from Limited Partners (LPs) to deliver high returns within short fund lifecycles. Yet, the core value-creating segments in HealthTech, such as complex AI-enabled medical devices or drug discovery platforms, have clinical and regulatory timelines that demand five to ten years to achieve regulatory approval and a successful exit. The market attempts to resolve this inherent conflict by accepting high entry valuations—often reported to be three to five times higher than in other sectors. A financial market correction will instantly expose this temporal gap, forcing GPs to accept lower internal rates of return or face massive write-downs on portfolios built upon speculative clinical timelines. HealthTech Valuations: The AI Premium and Risk Assessment A. The Quantified AI Valuation Multiplier and M&A Dynamics The AI integration into HealthTech is directly responsible for a quantifiable valuation multiplier. AI-enabled startups command an 83% premium in funding, reflected by an average funding round size of $34.4 million compared to $18.8 million for non-AI firms. This premium extends across early and middle stages, with Series A and Series B deal sizes seeing significant inflation. This capital flow reflects the investor consensus that AI is a necessary, high-growth asset class. While deal volume has declined, the M&A landscape shows that valuation multiples were climbing their way back up to 2021 levels as of Q1 2025. This suggests frothy, highly selective pricing for premium AI assets, with average revenue multiples in M&A transactions ranging between 4x and 6x. B. Stress-Testing Valuation Methodologies The systemic risk flagged by the BoE directly compromises conventional private market valuation practices. The Venture Capital (VC) Method, which relies heavily on projecting high expected returns at the time of exit , is most vulnerable. A sudden, sharp repricing of public AI stocks, resulting from a macro correction, immediately invalidates the crucial exit multiple assumption used in VC calculations. Furthermore, traditional Discounted Cash Flow (DCF) analysis, typically suited for more mature startups with consistent revenue , is often poorly applied to early-stage AI companies. These firms typically lack the operational history and predictable revenue visibility required for robust, long-term DCF projections, forcing reliance on speculative, market-driven valuation methods that are easily invalidated during a downturn. The ultimate risk is the sudden reversal of compressed risk premia. The FPC warned that investors had not fully accounted for potential downside risks. A market correction represents the violent, sudden, and forced repricing of that risk. The currently compressed risk premia, noted by the BoE , will instantly snap back to historical averages, triggering violent valuation compression across private markets overnight. C. Erosion of the AI Moat and Public Market Discipline The 83% valuation premium afforded to AI HealthTech is only justified if the AI component creates a durable competitive moat. However, the decreasing cost of developing and implementing generalized AI is intensifying competition. During a correction, investors will aggressively distinguish between companies that are merely "AI-enabled" (those using third-party large language models) and those that possess "Proprietary AI" (owning unique foundational models, deep clinical intellectual property, or specialized, inaccessible datasets). The valuation premium will entirely vanish for the former, leading to the steepest valuation falls. For example, the success of AI scribes, a hot segment, could quickly dissipate if major electronic health record (EHR) vendors integrate free competing tools. This macro pressure is quickly transmitted to the private market through the public exit environment. The recent, tentative thawing of the IPO freeze, marked by companies like Hinge Health and Omada Health making notable debuts , signaled a crucial opening for private market liquidity. However, the BoE's alarm signals that this fragile exit window could immediately slam shut. As a direct consequence, private market valuations, which had been creeping up toward 2021 levels , will stall or reverse instantly. Late-stage venture investors will rapidly impose aggressive financial covenants, including down rounds and stringent anti-dilution measures, to protect their existing capital against anticipated public market turbulence, thereby trapping late-stage HealthTech companies that need near-term liquidity. Deep Dive: Vulnerability Segmentation of AI HealthTech Sub-Sectors The impact of a market correction will vary dramatically across HealthTech sub-sectors based on their maturity, regulatory burden, and proximity to tangible revenue generation. The following table provides a matrix for assessing differential risk exposure: HealthTech AI Sub-Sector Risk and Funding Profile Sub-Sector Primary Function/Value Funding Reliance (Risk Exposure) Clinical/Regulatory Barrier Valuation Vulnerability AI Drug Discovery (AIDD) Target identification, synthesis route prediction, accelerated R&D Extremely High (5-10 year runway needed) Very High (Zero drugs approved) Highest (Extreme clinical timeline mismatch) Diagnostic/Patient AI Imaging analysis, triage, clinical decision support Medium-High (Requires validation trials) High (Systemic failure/Bias risk) High (Trust deficit, regulatory scrutiny) Administrative/Operational AI Provider operations, cybersecurity, billing, data analytics Low-Medium (Clear, rapid ROI) Low (Primarily data governance/compliance) Lowest (Defensive, demonstrable cost savings) A. High-Risk, High-Reward: AI Drug Discovery (AIDD) AIDD represents the high-water mark of speculative investment, attracting massive capital based on the promise of revolutionizing R&D, streamlining drug discovery, and reducing costs. However, this segment is defined by the "Clinical Chasm": despite substantial investments over the last decade, "few AI-discovered or AI-designed drugs have entered human clinical trials, and none have achieved clinical approval" as of late 2024/early 2025. This lack of validated results, coupled with the long development lifecycle—where VC-backed companies aim for an exit in 3-5 years, but pivotal clinical trials can take up to 10 years for FDA approval —makes AIDD the most exposed sector to a sudden capital market freeze. High burn rates combined with protracted regulatory timelines guarantee that a market correction will immediately challenge the survival of all but the best-capitalised and clinically-validated AIDD platforms. B. Systemic Clinical Risk: Diagnostic and Patient-Facing AI AI used in diagnostics, triage, and patient-facing clinical decision-making carries a unique, systemic clinical risk. While 83% of doctors view AI as a net positive, a striking 70% express serious concern regarding its use in the diagnostic process. This apprehension is well-founded, given reported instances of AI "hallucinating" transcriptions. The risk is magnified because a single inaccurate or biased medical algorithm, trained on non-representative data, could propagate clinical errors across thousands of patients simultaneously, escalating an isolated error into a systemic healthcare crisis. Furthermore, the "black box" nature of many deep learning models prevents clinicians from identifying the specific data points that influenced the AI’s conclusion, forcing doctors to rely on outputs they cannot independently verify. A correction scenario is likely to accelerate regulatory scrutiny, penalising companies that failed to proactively address issues of data bias and model transparency, thereby adding friction to an already uncertain commercial pathway. C. Defensive Positioning: Administrative and Operational AI This sub-sector, encompassing provider operations, cybersecurity, and administrative data analytics, holds a defensive position in a correction. These tools deliver quantifiable productivity gains and cost reduction, focusing on pain points such as anti-money laundering, fraud combatting, and cybersecurity. This rational value proposition led to Administrative HealthTech generating 50% of 2024 HealthTech AI investment, translating to $4 billion in funding. While delivering benefits, the sector introduces new, critical systemic risks related to operational resilience. The increasing reliance on external providers for AI-related services, predominantly Big Tech firms, exposes financial institutions to heightened concentration risks, potentially making these third-party providers systemically critical. D. Systemic Opportunity Cost and Regulatory Shifts The intense focus on the risks of overvaluation must be balanced against the parallel risk of AI underuse in healthcare. The failure to fund transformative but capital-intensive clinical AI systems due to a funding crisis imposes a high societal "opportunity cost," which economists define as the difference in productivity and quality gains between an AI-supported health system and one that does not utilise AI sufficiently. This zero-sum economic outcome, the potential loss of delayed drug breakthroughs or missed diagnostic efficiencies—underscores why investors must continue highly selective funding for capital-efficient, clinical AI platforms with strong early data, positioning them as essential societal infrastructure rather than pure speculative tech bets. Concurrently, the BoE’s focus on cybersecurity as the highest potential systemic risk necessitates a shift in investor due diligence. HealthTech is uniquely vulnerable; analyses show 90% of healthcare organizations expose sensitive data to AI tools due to governance failures, including widespread use of "shadow AI" and the presence of "ghost users". Investors must mandate a stringent cyber-risk assessment, immediately penalizing companies with inadequate security posture regarding third-party data reliance and unsanctioned generative AI usage. This is vital because security failures represent unmitigated liability risks, resulting in catastrophic regulatory fines (e.g., HIPAA and GDPR) that a startup cannot survive during a funding winter. Consequences of Deleveraging: Operational Impact on HealthTech Startups A. The Regulatory and Clinical Trial Crunch A macro-financial correction immediately translates into an operational crisis for early-stage HealthTech companies. Economic uncertainty, market volatility, and stringent regulatory barriers combine to make capital acquisition demonstrably more "difficult and more expensive" for high-risk ventures. Venture capital is crucial for financing pivotal studies and accelerating the development milestones required for US Food and Drug Administration (FDA) approval. When global finance dries up, a direct risk cited by the BoE FPC , R&D expensing and critical clinical trials are immediately jeopardized, delaying the time-to-market for digital therapeutics and novel devices. The intrinsic difficulty of obtaining regulatory approvals, which increases costs and creates uncertainty , is multiplied by a capital contraction, making the already long 5-to-10-year runways impossible to sustain for the vast majority of startups. B. The Mandate for Operational Efficiency and Interoperability To survive a deleveraging event, HealthTech operators must embrace "smart growth" strategies centered on capital efficiency and regulatory compliance. The cultural chasm between traditional tech, which champions the "move fast and break things" ethos and clinical healthcare, where product risks require teams to "proceed with caution", is amplified by the funding crunch. Investors will now reward AI firms that embed risk management, clinical safety, and regulatory competence into their core operating model, favoring clinical and operational experts over pure technologists. Operational survival also hinges on ensuring product stickiness and alignment with market dynamics. The commercial strategy must pivot from selling raw technology to integrated solutions that demonstrate verifiable, positive impacts on physician workload and interoperability. Companies that successfully integrate their AI applications into value-based care models, delivering both increased efficiencies and better outcomes, are best positioned to navigate chronic reimbursement headwinds and sustain growth during an economic slowdown. Furthermore, the restoration of R&D expensing in certain jurisdictions allows companies to reclaim deductions for software development, AI training, and clinical trials. Management teams must leverage these financial tools to aggressively build intellectual property moats against competitors, making their technology difficult and costly to replicate. C. The Rise of the 'Capital-Efficient Moat' In a recessionary environment, the market will decisively favor HealthTech solutions that prioritize capital efficiency.While the development of large foundation models requires vast computational resources , the immediate investment priority must shift to platforms that can scale rapidly with minimal additional capital expenditure. This favors solutions, typically in the administrative or operational AI space, that utilize existing enterprise infrastructure (cloud services, EHRs) and deliver immediate, quantifiable labor cost savings. These solutions offer a clear, defensible return profile, establishing a "capital-efficient moat" that outperforms bespoke, research-intensive AIDD platforms in a constrained funding environment. Strategic Recommendations for Investors and Operators The Bank of England’s warning is a crucial signal for risk mitigation. The following recommendations provide a strategic playbook for institutional investors and HealthTech management teams to navigate the impending market volatility. A. Investment Due Diligence: Mitigating Bubble Contagion De-risking Valuation Assumptions: Investors must immediately stress-test all portfolio company valuations against a projected 30% to 50% decline in public market tech multiples, which represents a realistic hard landing scenario. Investment models must be revised to incorporate plausibly lower exit multiples and extended time-to-exit horizons (7 to 10 years), reflecting the inherent clinical gestation time. Forensic Moat Analysis: Due diligence must demand verifiable evidence of proprietary data access, deep algorithmic innovation, and robust clinical validation. Companies that provide only a superficial user interface layered atop a commoditized foundation model must be aggressively de-valued, as their premium will not survive a correction. Operational Risk Scoring: A new emphasis must be placed on operational compliance. Investors should prioritize companies that demonstrate strong internal governance over data privacy, data security, and the control of shadow AI usage, recognizing that failures in these areas introduce unmitigated legal and regulatory liability risks that can cause existential failure. Distressed Asset Strategy: Institutional investors should prepare capital to acquire distressed assets resulting from either the lingering 2021 valuation bubble or the new AI correction. The focus should be on securing strong intellectual property, unique data assets, or proven clinical data, which may become available at significantly reduced valuations from companies that failed to manage their capital burn. B. Operational Strategies for HealthTech Management Survival Embrace Capital Efficiency and Extend Runway: Management teams must prioritize core revenue generation and aggressively extend their runway. The ability to pivot quickly and maintain a clear, defensible path to profitability is paramount for survival in a volatile funding environment. Build a Regulatory and Clinical Fortress: Regulatory engagement, compliance planning, and clinical validation must be treated as critical, non-negotiable capital expenditures. Clear, defensible clinical results and proactive mitigation of bias/black box risks are the ultimate commercial shields against valuation critique and regulatory friction. Prioritise Provider Workflow Integration: Commercial strategies must shift entirely from marketing abstract "technology" to providing "integrated solutions" that demonstrably ease physician workload and improve interoperability within existing healthcare IT infrastructure. This deep integration ensures contract stickiness, crucial for maintaining revenue during an economic slowdown. Leverage R&D Tax Benefits: Companies must fully utilize available tax provisions, such as the restoration of full expensing of research and development costs, to maximize deductions for software development and clinical trials, effectively minimizing taxable income and freeing up cash for operations. The current market is fundamentally characterized by an aggressive sorting process, contrasting the valuation metrics seen during the last major HealthTech peak against the selective funding climate of 2025. HealthTech Valuation and Investment Dynamics Comparison (2021 Peak vs. H1 2025) Metric 2021 Peak H1 2025 Change/Implication Total Annual Cash Raised (Index 100) Peak Down 58% (vs. 2021 annual total) Sharp reduction in overall market funding volume; constrained environment. Average Deal Size (Digital Health) Lower (Broad funding base) $26.1 million (Multi-year high) Capital concentrated into fewer, larger, later-stage AI-focused companies. AI Funding Allocation (Digital Health) Lower Percentage 62% of VC dollars AI established as the strategic funding focus and primary valuation driver. M&A Multiples High Climbing back towards 2021 levels Buyers are intensely selective but willing to pay premium multiples for proven, high-quality AI assets. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading Healthcare AI M&A Advisors in Europe? Executive Summary and Strategic Context The European Healthcare AI mergers and acquisitions (M&A) landscape for 2024 and 2025 is characterised by a strategic shift away from broad volume toward concentrated value, driven almost exclusively by the imperative to acquire advanced artificial intelligence (AI) capabilities. Advisory services in this domain must navigate a highly nuanced market defined by stringent new regulations, intense competition for proprietary technology, and a persistent focus on profitability. Defining the European Healthcare AI M&A Landscape (2024-2025 Trends) The European M&A market demonstrated significant resilience in 2024. While global deal volumes saw a decline of 9%, overall European M&A deal value increased by 16% compared to 2023. This activity is symptomatic of a "flight to quality," where highly differentiated companies attract competitive auctions and command higher prices. This trend establishes that the success of M&A in this region is dependent on strategic selection and high-quality due diligence, rather than sheer transaction execution speed. The valuation landscape within European HealthTech is fundamentally reshaped by technology and data compliance. AI remains the single largest driver of valuation premiums, particularly for companies that possess clinically validated, proprietary AI algorithms and demonstrate deep integration capabilities within existing healthcare workflows. Companies specialising in premium segments such as AI and advanced analytics are commanding premium valuations, typically ranging from 6x to 8x revenue multiples or more. Furthermore, deal activity is heavily influenced by convergence: non-technology companies acquiring technology firms represented 12% of total M&A volumes in 2024, nearly doubling the 7% long-term average. This marked increase reflects a broader rebalancing of industry focus toward growth sectors like healthcare and technology, confirming that M&A is increasingly driven by the acquisition of core capabilities needed for future competitiveness, rather than simple cost consolidation. The Dual Advisory Model: Scale vs. Specialisation Identifying leading advisors in Healthcare AI M&A requires separating firms based on their primary value proposition. The market effectively splits advisory services into two crucial categories, each essential for different transaction sizes and complexities. First, there are the Global Investment Banks (Tier 1), which dominate in terms of overall deal value, access to global capital, and the capacity to handle multi-billion-dollar transactions, major public company acquisitions, and complex debt structuring. These firms are necessary for executing large-scale convergence plays involving major pharmaceutical companies or large private equity (PE) funds. Second, the Specialised Boutiques (Tier 2) are critical for transactions where deep technological validation and niche regulatory understanding are paramount. These firms often possess superior real-time market knowledge of early-stage or mid-market AI platforms and are highly effective in managing the idiosyncratic risks associated with proprietary digital health intellectual property (IP). The increasing technical complexity of targets necessitates this specialized expertise, ensuring that acquirers accurately value and effectively integrate core AI assets. Tier 1: Global Investment Banks and Full-Service Leaders The world’s leading investment banks continue to lead the European M&A tables, demonstrating their essential role in providing capital access and market liquidity for the largest, most strategically significant HealthTech transactions. Goldman Sachs (GS): The Leader by Value and Strategic Transformation Goldman Sachs firmly established its position as the top M&A financial advisor in Europe in 2024 by value, advising on a substantial $97.5 Billion worth of deals. This top ranking was achieved following a significant year-on-year growth, registering more than a double-fold jump in the total value of deals advised during 2024 compared to 2023. This performance confirms the firm's unparalleled capability in structuring and financing mega-deals. The firm's strategic focus aligns directly with the future of Healthcare AI M&A. GS explicitly anticipates that the rebalancing across industries toward growth-focused sectors, particularly technology and healthcare, will continue, projecting that AI-related M&A will "gain steam" in 2025. This institutional belief in the acceleration of AI-driven deals confirms the expectation that the next generation of multi-billion dollar transactions in the healthcare space will be defined by technological capability enhancement. The firm's involvement in major financing arrangements, such as serving as a financial advisor on debt commitments for the $6.75 Billion acquisition of Press Ganey Forsta (a deal focused on AI-powered experience management), underscores their role in funding large transactions at the intersection of technology and regulated industry. GS’s success is therefore heavily tied to its ability to anticipate and facilitate these AI-driven convergence plays, positioning it as the necessary partner for large, capital-intensive buyers. Rothschild & Co: The Leader by Volume and Independent European Coverage In contrast to volume, Rothschild & Co distinguishes itself through market coverage, maintaining its consistent position as the top M&A financial advisor in Europe in 2024 by volume, having advised on a total of 132 deals. Rothschild has held this volume leadership position for over 15 years in Europe. While volume leadership might appear distinct from the high-value deals of competitors, it is crucial for generating superior, real-time intelligence across the fragmented European market. Rothschild’s high volume is indicative of deep coverage in the mid-market, which is precisely where many emerging and specialised European AI HealthTech firms are concentrated. This pervasive network, extending across 42 countries, provides an indispensable advantage for acquirers seeking to rapidly screen and identify critical strategic assets across diverse regulatory and legal environments. The firm supports this broad coverage with dedicated sector expertise. For example, in London, Thibault Poirier serves as a Managing Director focusing specifically on Healthcare Services and Healthcare Technologies. Additionally, Dominic Hollamby, Executive Vice Chairman of Global Advisory, serves as the Chairman of Healthcare, providing senior leadership and experience, having previously worked within the UK’s National Health Service. This dual strength in high-volume coverage and dedicated sector teams makes Rothschild essential for mapping and executing acquisitions across the entire ecosystem. Firm 2024 Rank by Metric Primary Metric Achieved Reported Deal Value (2024) Relevance to HealthTech/AI Strategy Goldman Sachs #1 by Value Value $97.5bn Unparalleled access to global capital markets; leading advisor on capability-enhancing and large-scale technology convergence deals Rothschild & Co #1 by Volume Volume (132 deals) N/A (Ranked #9 by Value) Deepest European market coverage; consistent leadership in mid-market transactions essential for identifying niche AI assets Tier 2: Specialised Boutique and Mid-Market AI/HealthTech Advisory While Tier 1 banks provide the scale and capital, specialized boutiques offer the critical technological and regulatory granularity necessary for valuing and transacting proprietary Health AI assets. These firms are essential risk mitigators in a highly technical sector. Nelson Advisors: European HealthTech AI Specialisation Nelson Advisors is positioned as a highly specialised M&A advisory firm with an exclusive dedication to the dynamic European healthcare technology (HealthTech) sector, with advisory reach across the UK and North America. This focused dedication forms the bedrock of their value proposition, enabling a nuanced understanding of the technological advancements and market dynamics that are critical for successful transactions within this complex industry. The firm's expertise is specifically tailored to complex technological verticals, including Mergers, Acquisitions & Partnerships for Digital Health, Health IT, Consumer HealthTech, Healthcare Cybersecurity, and, crucially, Healthcare AI companies. Nelson Advisors is known as a top boutique advisor in this space, providing personalised M&A and investment guidance. Their deep sector specialisation is vital for navigating the niche regulatory and technological complexities that often define founder-led sales and venture-backed exits in Europe. Artis Partners: Focused AI and DeepTech Mandates Artis Partners is a fledgling boutique investment bank explicitly built to capitalise on the artificial intelligence investment boom by providing M&A advisory services for technology in the US and Europe. The bank maintains a narrow, strategic focus on advising AI companies or technology companies that utilise AI, with its clientele base split equally between the US and Europe. Approximately 30% of its business is devoted to advising AI companies on fundraising and M&A, demonstrating a significant commitment to this technological vertical. The firm has demonstrated proficiency in relevant European transactions. For instance, Artis advised on Mindler's acquisition of ieso Digital Health UK, a leading provider of digital mental health therapy, a transaction that successfully created a pan-European leader in the digital sector. Furthermore, Artis advised shareholders of Ravelin, an AI-native fraud prevention platform, on its sale to Worldpay. Although Ravelin operates in the fintech sector, the successful M&A execution of an AI-native platform proves Artis’s core competency in valuing and transacting proprietary AI intellectual property (IP), which is a key technical skill directly transferable to the Health AI sector where IP valuation drives premium multiples. This ability to conduct sophisticated diligence on the core technological asset mitigates the risk of overlooking technical flaws in AI architecture post-acquisition. Regional and Segmented Specialists Beyond the cross-European boutiques, regional specialists often possess localised regulatory and market intelligence necessary for specific strategic goals. Nordic M&A is prominent in the Nordic region, focusing on Health Technology and IT within its dedicated healthcare unit. The firm’s unit is led by a Dr. with an MBA, and is supported by a scientific board of international experts. This combination of a medical background and M&A skills provides them with a rare and valuable ability to quickly understand the true clinical and business value models of life science and health technology companies. For acquirers targeting the highly innovative Scandinavian technology hubs, this specialised understanding is critical for successful deal completion. TH Healthcare & Life Sciences, a division of Technology Holdings, focuses investment banking exclusively on the Healthcare & Life Sciences Company Ecosystem Globally.This dedicated focus provides sector-specific expertise and ensures a deep understanding of the unique dynamics within HealthTech. Leading Boutique M&A Advisors Focused on European Healthcare AI Firm Primary Geographic Focus Core Specialization AI/Digital Health Focus Level Key Insight Nelson Advisors UK, Europe, North America HealthTech, Digital Health, Health IT Exclusive dedication to AI-driven health solutions Deep sector specialization is essential for navigating niche regulatory and technological complexities in founder-led sales. Artis Partners Europe and US (50/50 split) B2B SaaS, DeepTech, Healthcare Technology Narrow focus on advising AI companies Proven track record in executing M&A for AI-native platforms and cross-border digital health assets. Nordic M&A Nordic Region Healthcare Services, Health Technology and IT High relevance due to combined medical/M&A background Critical for acquirers targeting Scandinavian innovation hubs, leveraging clinical understanding in diligence. The Influence of European Regulatory Frameworks on Dealmaking The quality of M&A advice in European Healthcare AI is intrinsically linked to the advisor’s ability to anticipate and integrate regulatory changes. The two pivotal frameworks currently shaping the market are the EU AI Act and the European Health Data Space (EHDS). The EU AI Act (August 2024): A Compliance Imperative The implementation of the EU AI Act, scheduled for August 2024, is a critical framework shaping the market. Health AI systems often fall under the "High-Risk" category of the Act, which mandates rigorous compliance and governance requirements. This framework fundamentally alters the due diligence process for acquirers. Crucially, compliance with the Act is transforming from a passive risk assessment into an active, quantifiable value driver. Regulatory clarity provided by frameworks like the EU AI Act is boosting investor confidence. High-quality, compliant assets are now attracting a significant "regulatory premium," potentially adding a 0.5 to 1x multiples lift to the valuation. This means that the compliance status of an AI target must be a core line item in the financial model, not just a liability in the legal memo. Financial advisors must coordinate with legal experts to rigorously quantify the gap between a target company's current compliance posture and the forthcoming EU standards to avoid massive integration and operational risk post-acquisition. The ability of an advisor to accurately model this premium, and consequently expedite the acquisition of compliant assets, generates significant alpha for the client. The European Health Data Space (EHDS) (March 2025): Data Interoperability and Valuation Slated for implementation in March 2025, the European Health Data Space (EHDS Regulation) is designed to create a unified and trustworthy environment for health data exchange. This regulatory development directly impacts how data-driven assets are valued. Firms that can ethically and effectively leverage patient data and offer solutions that integrate robustly with Electronic Health Records (EHRs) are commanding higher multiples, typically in the range of 5.5x to 7x revenue. The EHDS emphasises interoperability, meaning financial and strategic advisors must evaluate a target’s architectural readiness not just for current clinical workflows, but for its future capability to share and access data seamlessly across various EU member states. This transforms interoperability from a technical feature into a key component of scalability and valuation. The combination of the AI premium and the regulatory premium arising from both the AI Act and the EHDS amplifies the "flight to quality," ensuring that only companies with verified technological sophistication and adherence to clear regulatory paths command top prices. Key European Regulatory Drivers and Impact on Healthcare AI M&A Regulation Expected Implementation (Target Date) M&A Impact on Target Companies Advisory Implication EU AI Act August 2024 Mandatory compliance assessment based on risk classification; drives "regulatory premium" Legal and technical DD must map AI system risk; financial advice must integrate compliance costs/premiums into valuation models. European Health Data Space (EHDS) March 2025 Boosts valuation for interoperable, ethically managed data platforms; mandatory data sharing standards Financial analysis must quantify data monetization potential and assess integration readiness with EHRs and cross-border platforms. Outlook and Recommendations for Dealmakers The European Healthcare AI M&A market is entering a phase of accelerated strategic activity, demanding a composite advisory approach that leverages both the scale of global banks and the technical depth of specialised boutiques. Strategic Advisory Recommendations based on Acquirer Profile For potential acquirers, the selection of an advisory team should be based on the strategic objectives and the necessary scale of execution: For Large Corporates and Multinational Pharma: When the mandate involves acquiring scale, accessing global capital markets, or executing major cross-border divestitures (such as the $20 billion 3M healthcare spin-off, Solventum Corporation), the engagement of a Tier 1 global bank is indispensable. The recommendation is to pair a financial advisor like Goldman Sachs (for value and scale) or Rothschild & Co (for volume and European coverage) with a legal firm possessing deep cross-sector competence, such as Goodwin Procter LLP or Latham & Watkins with a dedicated Life Sciences/Technology focus. This structure ensures optimal financing and management of complex regulatory and antitrust risks. For Private Equity (PE) and Venture Capital (VC) Funds: When the focus is on acquiring niche platforms, conducting thorough technical due diligence on proprietary IP, or executing mid-market transactions, Tier 2 specialised boutiques are highly advisable. Firms like Nelson Advisors or Artis Partners possess the necessary technical expertise to verify the proprietary nature of AI algorithms and accurately assess regulatory exposure under the EU AI Act. Their focused expertise reduces the risk of technological misevaluation, which is the paramount risk factor in Health AI acquisitions. Key Trends for H2 2025 and 2026 The market is poised for a significant uplift in both volume and average deal size. As CEO confidence rises and expectations of regulatory normalisation take root, a new wave of M&A activity is expected, with AI remaining the dominant catalyst. This trend is supported by the increasing number of $10 Billion-plus deals globally, which rose by 26% year-over-year in 2024, and the forecast for a meaningful pickup in 2025 across technology, healthcare, and financials. Furthermore, Europe is experiencing strong momentum in take-private activity, a trend particularly favorable for private equity deployment in the technology sector amidst attractive valuations. EMEA saw the strongest acceleration globally, with take-private deal activity rising 34% year-over-year in 2024, and soaring 84% year-over-year in the UK. Advisors expert in structuring complex take-private deals will be critical for PE funds leveraging a declining rate environment. Conclusion: The Mandate for Integrated Advisory The future success of European Healthcare AI M&A hinges on the advisor's ability to seamlessly integrate financial expertise with technical and regulatory risk modeling. The complexity of validating AI solutions, ensuring data privacy compliance under the EHDS, and classifying risk levels under the EU AI Act requires advisory teams to act as multi-disciplinary consortium managers. The financial model must incorporate the quantifiable 0.5 to 1x regulatory premium, which can only be accurately assessed via the deep technical due diligence traditionally provided by specialised boutiques or dedicated technical teams. Therefore, the leading advisory strategy involves a coordinated effort: utilising the scale and capital access of a Tier 1 firm for execution, while mandating deep, specialised due diligence from Tier 2 firms and expert legal counsel to maximise value and minimise post-acquisition liability in this highly regulated and technologically advanced sector. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

This Week in European HealthTech and MedTech: 5th October 2025 The top stories in European HealthTech this week are heavily focused on AI adoption, major regulatory milestones, and significant funding activity. Here are the key highlights: 1. AI Regulation Breakthrough for Autonomous Care AI Physiotherapist Approved for Autonomous Decisions: A significant development saw Flok Health's AI-powered physiotherapy clinic secure Class IIa Medical Device approval under EU regulations. This is a major regulatory milestone, as it grants the AI system clearance to make diagnostic and treatment decisions without human supervision, effectively delivering an entire end-to-end care pathway autonomously. This is reported to be the first time an AI system in the UK or Europe has been approved for fully autonomous end-to-end care. 2. Notable Funding Rounds The week has seen fresh capital injection for AI-powered and wellness platforms: Simple Life's Major Series B: The London-based wellness and fitness app, Simple Life, secured a $35 million Series B funding round to scale its AI health coach platform. praxipal's Seed Funding: Berlin-based startup praxipal landed $6.7 million to continue building its AI workforce designed for healthcare front desks in Germany. Vocca's Seed Round: The voice AI startup Vocca raised $5.5 million in seed funding to bring AI phone assistants to the healthcare sector. DaltonTx Seed Funding: UK-based technology company DaltonTx exited stealth and completed a £4 million seed round to advance its intelligence backbone for drug discovery. 3. Focus on Digital Health in Healthcare Systems (Primarily UK/NHS) Major Digital Strategy and Procurement: Several health systems across the UK are pushing forward with significant digital transformation projects: University Hospitals Birmingham is seeking a £2 million integrated digital patient pathway platform. GOSH (Great Ormond Street Hospital) shared a study into an AI scribe pilot across nine London NHS sites, and also outlined its comprehensive AI strategy roadmap. Lincolnshire Community and Hospitals NHS Group launched its digital strategy to 2028. Pilot data showed that Flok Health's AI physiotherapy platform had a measurable impact, more than halving waiting lists for back pain at one NHS Trust. 4. Innovation in Diagnostics and Patient Monitoring Regulatory Approvals for Danish Startups: Evido Health obtained regulatory approval (CE-certificate, IVDR cl-b) for its data-driven clinical tool, LiverPRO, aimed at timely detection and intervention for Chronic Liver Disease (CLD). BrainCapture received CE marking for its pioneering, affordable EEG solution. WARD 24/7 received FDA Clearance for its WARD-CSS® (Clinical Support System), a Software as a Medical Device (SaMD) for continuous patient monitoring. In summary, the European HealthTech landscape is demonstrating strong momentum, particularly in the fields of AI-driven clinical applications with a landmark regulatory approval, sustained early-stage and growth-stage funding, and continuous digital modernisation efforts within public healthcare systems. This Week in European HealthTech and MedTech: 5th October 2025 The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices. Here are the top stories: 1. Regulatory Pressure and Calls for MDR/IVDR Reform The central theme this week is the ongoing industry push for revisions and accommodations within the European Union's medical device regulations (MDR/IVDR): EU Call for Evidence for MDR/IVDR Future: The European Commission launched a "Call for Evidence" on the future of the MDR/IVDR, specifically a targeted revision aimed at reducing administrative burden, improving predictability, and enabling digitalisation. The deadline for industry feedback is October 6, 2025, making this the most time-sensitive policy story this week. MedTech Europe's Push for Immediate Action: The industry body, MedTech Europe, continued to press the EU for immediate regulatory changes by early 2026. Their requests include: A targeted postponement of re-certification requirements for devices already certified under the existing regulations to avoid a "new major bottleneck" before the 2028 deadline. The creation of a single, accountable governance structure to oversee the network of Notified Bodies (NBs), aiming to ensure a more efficient and globally competitive CE-marking system. The launch of planned pilots for expedited regulatory pathways for orphan, pediatric, and breakthrough devices. Regulatory Milestones: The industry saw updates on several detailed compliance issues: Confirmation of the Master UDI-DI (Unique Device Identification) implementation date for contact lenses being postponed to November 9, 2026. Publication of new guidance on addressing incomplete Technical Files for IVDR submissions from Team-NB. Updates on the status of MDR/IVDR implementation and the gradual rollout of the EUDAMED database. 2. MedTech Product Rollout and Commercial Growth Cardiology Device Rollout: Elixir Medical began its full European rollout of the LithiX high-capacity Intravascular Lithotripsy (IVL) device following its CE mark, with over 400 patients already treated across 16 countries. This marks a significant market entry for a new cardiology technology. 3. Key MedTech Funding and Expansion Recent funding activity highlights strong investment interest in both digital and hardware-based medical solutions: Remote Monitoring Device Funding: RDS (France) raised a €14 million Series A round to industrialise and expand its MultiSense RDS, a CE-marked connected patch for continuous remote patient monitoring across Europe. AI for Veterinary MedTech: Lupa (UK) secured a €17 Million Series A to scale its AI-native operating system for veterinary clinics and launch a dedicated Veterinary AI Lab in Europe, demonstrating the spread of MedTech innovation into adjacent healthcare sectors. Big Tech Investment in Surgical Robotics: Medtronic plc announced it is doubling its London presence to create a global hub for surgical robotics and AI, aligning with the ambitions of the NHS 10-Year Health Plan. 4. Broader Context and Industry Movement Staffing and Leadership: Dentsply Sirona appointed a new EVP & Chief Commercial Officer to align its global business units with commercial execution, with the new executive bringing extensive experience from J&J MedTech. Global Trade Impact: European MedTech firms are closely watching the potential impact of a US Section 232 investigation and its potential to introduce tariffs, particularly monitoring whether it could override the Nairobi Protocol, which bans tariffs on products for people with disabilities. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Bamboo Mindset: A Strategic Framework for Flexibility, Resilience and Sustainable Growth in HealthTech Executive Summary: The Strategic Mandate for Bamboo in Healthtech The HealthTech industry operates at the critical confluence of rapid technological velocity and necessary regulatory gravity. This dynamic tension, exemplified by the swift advancement of digital innovation (e.g., AI/ML) encountering historically complex and risk-averse regulatory frameworks (such as HIPAA and FDA oversight), demands an organisational philosophy built not on rigidity, but on adaptive strength. The Bamboo Mindset, defined by its core pillars of Flexibility, Resilience and Steady Growth, provides the essential strategic model for achieving long-term organisational viability and maintaining patient trust. The application of this mindset is the organisational imperative, addressing key friction points such as the fragmented US regulatory patchwork, the threat of sophisticated cyberattacks, and the ethical pressure for rigorous clinical validation of Artificial Intelligence. Strategic success requires organisations to transcend static, reactive compliance models and embrace anticipatory regulatory design; to fortify systemic defenses against catastrophic shocks; and to unequivocally commit to prospective validation to ensure patient safety and earned clinician adoption. The report culminates in three immediate prescriptive actions for leadership: formalising cross-functional compliance governance, mandating comprehensive security modernisation aligned with proposed HIPAA standards, and adopting a rigorous, prospective validation standard for all high-risk AI devices. Establishing the Foundation: The Bamboo Mindset as a Healthtech Metaphor The Volatile HealthTech Ecosystem: Drivers of Change and Complexity The health technology sector is characterized by an intrinsic strategic friction point: the rapid velocity of innovation versus the essential, but often slow, inertia of regulation. Technology, specifically AI-driven analytics and cross-sector data sharing, consistently advances beyond the scope and capabilities of established, decade-old frameworks like HIPAA. This structural friction mandates the adoption of a strategic model engineered to absorb continuous change without compromising clinical efficacy or patient safety. At the heart of the Healthtech mandate is the patient-centric imperative. Every strategic and operational decision must ultimately reinforce patient safety and sustain public trust. Organisational failures, whether manifested as widespread recalls due to device errors or catastrophic security incidents like the Anthem data breach, directly undermine this trust, incurring massive financial penalties and irreversible reputational costs. To effectively navigate this complex reality, organizations require tools to conceptualize and communicate strategic challenges. Metaphors, such as the Bamboo Mindset, serve this purpose by concretising abstract concepts, allowing leaders to convey shared interpretations of organisational experiences. The imagery of bamboo, deep roots, a strong spine, and the ability to sway with the wind without snapping, illuminates unperceived aspects of strategic challenges, fostering a unified response to external pressures. Defining the Three Pillars of Bamboo for HealthTech Operations The Bamboo metaphor describes an enterprise that is fundamentally rooted in its mission yet dynamically responsive to its environment. Flexibility (Regulatory Agility and Anticipatory Adaptation) Flexibility is defined as the organisational capacity to adapt to constant flux and "bend without breaking". In the context of global leadership, flexibility is recognised as a critically important quality. For HealthTech, this includes strategic patience ("non-action"-ness), radical adaptability, and participatory collaboration. Operationally, flexibility means transcending static, reactive compliance standards and adopting anticipatory regulatory approaches. This agility is essential because regulatory landscapes shift constantly, requiring leadership to model adaptability at the C-suite level to break down silos and enable swift institutional pivots in response to regulatory intelligence, such as evolving FDA classifications for consumer health tools. Resilience (Fortifying Against Shocks and Systemic Failure) Resilience is characterised by possessing a strong spine and deep operational roots, allowing the enterprise to successfully bounce back from adversity and withstand severe external shocks, the swirling winds of the market or adversarial attacks. HealthTech resilience specifically relates to establishing comprehensive cybersecurity defences, robust data governance protocols and the organisational fortitude required to manage high-impact events like major data breaches, mass recalls and systemic cyberattacks.This pillar ensures system survivability and maintains clinical function even under duress. Steady Growth (Deep Roots and Sustainability) Steady Growth emphasises the value of long-term, continuous, and measured expansion built upon rigour and validation. This requires cultivating a genuine growth mindset within the organisation, one that prioritises continuous learning, proactively seeks and welcomes constructive feedback, and continuously enhances patient safety. For technological products, this means rigorously prioritising prospective clinical validation, implementing stringent ethical AI governance and maintaining robust lifecycle controls to ensure sustainable market adoption and minimise the post-market vulnerabilities that erode patient and clinician confidence. Pillar I: Cultivating Flexibility through Regulatory Agility and Collaboration Navigating Regulatory Fragmentation: The Challenge of the Patchwork Framework The regulatory environment in the U.S. constitutes a significant strategic challenge due to its complexity and fragmentation. The current approach to privacy, characterised by a fragmented patchwork of state laws that attempt to fill the gaps left by federal frameworks, creates a severe financial and technical burden for entities processing personal data. This occurs because there is no harmonised framework, forcing entities to comply with a myriad of differing state requirements simultaneously. This compliance complexity directly increases the risk of data breaches, algorithmic bias, and patient data re-identification. Furthermore, the existing HIPAA framework, which is decades old, is inherently ill-equipped to address the complexities of the modern digital ecosystem, particularly the rapid evolution of AI-driven analytics and cross-sector data sharing. Organisational flexibility is also tested by the constantly shifting line between consumer wearables and regulated medical devices. The ambiguity surrounding these classifications can have immediate and significant market ripple effects. For instance, if a tool marketed for "wellness insights" is suddenly ruled by the FDA to be a medical device, it triggers requirements for rigorous FDA approvals, impacting everything from labelling to stock valuation. Strategic flexibility requires anticipating these regulatory shifts, such as the FDA's positioning on the Whoop blood pressure cuff and aligning the product development and marketing language accordingly to prevent abrupt and costly regulatory denial. Operationalising Flexibility: Agile Compliance True flexibility must be integrated into the core operational and development methodology of the healthtech company. 1. Integrating Agile Development Practices into Highly Regulated Product Lifecycles A pervasive, yet inaccurate, belief exists that Agile development methodologies are fundamentally incompatible with the stringent needs of highly regulated medical device development. This perception slows innovation. However, analysis indicates that many Agile practices are well-suited for these environments. When properly tailored to integrate rigorous documentation, verification, and validation into short, iterative sprints, Agile practices can actually accelerate compliance efforts. The core flexibility of the Agile Manifesto, which is not prescriptive, allows organisations to adapt the methodology to the complex reality of combined hardware and software development in MedTech. 2. Anticipatory Regulation and Iterative Development The highest form of flexibility is anticipation. Anticipatory regulatory approaches aim to develop compliance strategies iteratively, alongside the advancement of the new product or service. This model is more comprehensive than reactive compliance because it demands input from a highly varied selection of stakeholders, including legal, clinical, development, and IT experts, early in the process. This comprehensive, cross-functional input ensures a deeper understanding of regulatory requirements is achieved long before final submission. 3. Utilising Regulatory Sandboxes Regulatory sandboxes are valuable tools for testing flexibility and compliance. These environments allow HealthTech firms to test clinical and operational AI tools within clear legal and safety limits, particularly concerning data privacy and security. Since AI often requires substantial amounts of personal health data, sandboxes mandate enforcing strong privacy rules covering data use, storage, and sharing. Crucially, they allow IT workers to test system connections and cybersecurity performance under rule supervision and real-world conditions. Utilising these sandboxes provides documented proof of risk control and rule following, positioning compliance not merely as a necessary cost, but as a strategic risk mitigation asset. Breaking Silos: The Mandate for Cross-Functional Collaboration Flexibility demands organizational transparency and unity. During regulatory transitions, common obstacles such as communication breakdowns (where critical updates are siloed) and unclear roles prevent the organisation from reacting swiftly. The Bamboo Mindset requires the strategic combination of skills across clinical, IT, compliance, legal, and operations into streamlined, cross-functional teams. This unity is essential because the highly regulated nature of the industry means that innovation strategy must simultaneously incorporate complex regulatory standards, clinical efficacy, and data security. This collaborative structure acts as a critical risk mitigation mechanism. For example, integrating medical affairs with sales and marketing teams ensures that communication to healthcare professionals is evidence-based and compliant with all regulatory guidelines. Furthermore, establishing transparent, two-way communication channels, including regular weekly cross-team meetings—ensures that critical regulatory intelligence is broadly accessed, allowing teams to surface potential barriers early and prevent costly misunderstandings during development. The integration of lawyers and IT staff during sandbox testing minimises the expensive process of retrofitting compliance into a completed product. The strategic consequences of fragmentation and the necessary flexible adaptations are detailed below. The Regulatory Fragmentation Challenge and Flexible Adaptation Area of Complexity Healthtech Impact Bamboo Flexibility Strategy Fragmented U.S. Privacy Landscape High financial/technical compliance burden, risk of re-identification. Adopt unified, conservative data governance standards and 'Anticipatory Regulatory Approaches'. Evolving AI Regulation (e.g., EU AI Act) Compliance uncertainty, stringent requirements for high-risk systems. Utilise regulatory sandboxes to test compliance and cybersecurity under supervision. Distinguishing MedTech vs. Wellness Tools Market disruption, sudden changes to regulatory requirements and stock impact. Integrate compliance and legal teams early for product labelling and positioning; adopt continuous learning. Pillar II: Fortifying Resilience Against Systemic Shocks Organisational resilience is the operational imperative for maintaining system integrity and safeguarding patient trust against inevitable external and internal shocks. The Resilience Imperative in Health Data Management Case Studies in Failure: Analysis of Major Data Breaches Resilience is learned through the analysis of systemic failures. The Anthem data breach serves as a profound lesson in the financial and reputational consequences of insufficient security. The incident resulted in hundreds of millions of dollars in recovery expenses and legal fees, alongside massive reputational damages. Key lessons derived from this and similar events stress that data protection must be the uncompromised top priority, requiring effective security software and mandatory employee training, which is often the weakest link in the defence chain. Current Cyber Vulnerabilities and Exploitation The resilience of healthcare information systems was severely challenged by the organisational upheaval resulting from the COVID-19 pandemic. The necessity of rapid digital adoption introduced vulnerabilities that were quickly exploited by sophisticated attackers using methods such as ransomware, phishing campaigns, malware, and distributed denial-of-service (DDoS) attacks. This exploitation highlights that organisational inflexibility, the failure to rapidly update security protocols to meet new operational realities, creates security debt, which directly translates into systemic vulnerability. Therefore, resilience strategy must focus on system survivability: the capacity of clinical functions to maintain operation even when under duress. Defensive Strategies: Implementing Proactive Risk Mitigation Resilience must be structurally enforced, moving beyond optional safeguards to mandated controls. 1. Mandatory Modernisation of the HIPAA Security Rule Proposed updates to the HIPAA Security Rule aim to formalise risk management and substantially enhance data protection for entities handling ePHI. Crucially, the proposals intend to eliminate "addressable" safeguards, making all security controls mandatory requirements. This shift enforces a higher standard of structural resilience by requiring companies to address historically deferred security debt. 2. Implementing Enhanced Data Protection The modernisation framework mandates several specific controls essential for maintaining system resilience: Mandatory Encryption: All electronic protected health information (ePHI) must be encrypted both in transit and at rest. Multi-Factor Authentication (MFA): MFA is required for system access to prevent unauthorised breaches, recognising that single-factor authentication is inadequate against modern exploitation techniques. Risk Management: Annual risk assessments and vulnerability scans are required to proactively identify and mitigate system threats. Network Segmentation: This architectural control is necessary to isolate sensitive systems. By limiting the scope of system failure, segmentation ensures that a breach in one area does not lead to total systemic compromise, thereby protecting critical clinical functions. The Organisational Spine: Responding to Regulatory Setbacks Organisational resilience is ultimately demonstrated by the capacity to pivot strategically following significant failures or setbacks. Strategic Reorientation following FDA Complete Response Letters (CRLs) The FDA has moved toward increasing transparency, including the prompt public release of Complete Response Letters (CRLs). While beneficial for the broader industry, this means organisations must be internally resilient enough to reorient strategy rapidly following a formal denial. Resilience prevents market shock and allows for swift correction and re-submission. Developing a "Bounce Back" Culture The Bamboo Mindset requires setbacks, such as major recalls or regulatory denial, to be viewed as constructive learning opportunities rather than final failures. The analysis shows that market pressure often leads to fast launches and subsequent high rates of recalls. A resilient organisation counters this pressure by immediately strengthening lifecycle controls and enhancing post-market vigilance following regulatory clearance. By accepting constructive feedback and embracing organisational learning, firms can strategically transform regulatory compliance into a competitive advantage, proving risk control to both regulators and the patient population. The Resilience Matrix: Risk Mitigation and Recovery Threat Vector Operational Impact Bamboo Resilience Mechanism Major Data Breach (e.g., Anthem) Reputational damage, significant legal and recovery costs. Mandatory employee training, robust security software, and proper insurance/coverage. Cyberattacks (Ransomware, Phishing) System downtime, compromised PHI, loss of ability to deliver care. Modernised security safeguards: mandatory encryption, MFA, annual risk assessments, network segmentation. Regulatory Setback/Recalls Loss of clinician/patient confidence, financial penalties, market pressure. Proactive lifecycle controls, robust post-market vigilance, and organisational acceptance of constructive feedback. Pillar III: Ensuring Steady Growth through Validation and Ethics Sustainable growth is built upon the deep roots of clinical rigour, ensuring that innovation translates reliably and ethically into improved patient outcomes. The Danger of Untested Innovation: Market Pressure vs. Patient Safety The velocity of AI development, combined with external market pressures, often creates an environment where rigour is sacrificed for speed, leading to measurable systemic risk. The Correlation Between Lack of Validation and Post-Market Recalls The data establishes a clear vulnerability: AI/ML enabled medical devices (AIMDs) that lack prospective validation prior to receiving FDA clearance are significantly more likely to be recalled.2 This lack of rigor creates substantial operational risk; nearly half of all AI-related recalls occur within the first 12 months of FDA clearance.The majority of these recalls stem from internal errors, such as software and algorithm errors (e.g., incorrect dose calculations) and data integrity issues. The Pressure on Public Companies Market pressure is a key driver of non-sustainable growth. Public companies account for nearly all recalled units, suggesting a systemic incentive for faster launches without adequate clinical validation. The current regulatory structure, specifically the FDA’s 510(k) pathway, does not universally mandate prospective human testing. This regulatory allowance permits a non-sustainable growth model that is fast but shallow-rooted. Organizations adopting the Bamboo Mindset must actively reject the minimum viable compliance approach allowed by 510(k) and commit to prospective validation, making long-term safety the primary competitive differentiator. Clinical Validation: The Deep Roots of Trust The deep roots of steady growth are established by rigorous clinical validation that proves trustworthiness across diverse clinical environments. Establishing Real World and Diverse Population Testing Rigorous validation requires testing devices in real-world scenarios and across diverse patient populations to ensure consistent and reliable performance. This is essential because an AI device validated in one demographic or regional system may not perform equally well in another, directly impacting the generalisability of the model and potentially jeopardising safety. Thorough, generalisable clinical evaluation is challenging but non-negotiable for sustainable adoption. Strengthening Lifecycle Controls and Post-Market Vigilance Steady growth requires manufacturers to enhance post-market vigilance and strengthen lifecycle controls, thereby shifting the paradigm from reactive compliance to proactive risk mitigation. Continuous monitoring and refinement of deployed AI algorithms are mandatory to ensure that the tools maintain fairness and effectiveness as they encounter new data sets and evolving clinical environments. Ethical AI and Bias Mitigation for Sustainable Adoption Steady growth must be underpinned by strong ethical governance to secure clinician and patient trust. The Role of Clinicians in Vetting AI Clinicians are the essential human element in the deployment of AI. Feedback channels must be formalised to utilize their critical role in evaluating AI tools. Current evidence shows that doctors are uncertain about the predictive ability of AI and are not entirely reliant on AI-based disease detection.Steady growth is therefore contingent upon building a mutually beneficial relationship between AI systems and clinicians, where the operational ethos is "trust but verify". Ensuring Algorithmic Fairness and Safety The ethical requirement to mitigate bias directly aligns with the safety mandate. Since recalls are most often due to diagnostic or measurement-related errors, steady growth requires meticulous focus on core performance metrics, specifically accuracy, sensitivity, and specificity. AI development must align with best practices and patient safety goals, often guided by professional medical societies. The rigour of validation, ensuring reliability across diverse populations, is the prerequisite for widespread clinical adoption and earning mutual trust. Cultivating a Growth Mindset in Personnel and Leadership The sustained capacity for steady growth is rooted in an organizational culture committed to continuous learning. A growth mindset in personnel improves safety, positively impacting patient interactions and allowing the organisation to adapt readily to constant flux. Leadership must model this behaviour by welcoming constructive feedback and treating every challenge as a learning opportunity.This ensures that feedback from clinicians regarding deployed AI is utilised not only for product refinement but also as a mechanism for continuous organisational improvement. The table below outlines the relationship between the pace of growth, the associated risks, and the validation standards required to achieve a sustainable foundation. Framework for Steady Growth: Clinical Validation and Ethical AI Growth Stage Focus The Risk of Rushing Required Validation Standard (Deep Roots) Pre-Market Validation High rate of recalls within 12 months, stemming mostly from algorithm errors. Prospective clinical validation and human testing, strengthening lifecycle controls. Algorithm Performance Diagnostic errors, functionality delays, inconsistency across diverse patient populations. Rigorous measurement of accuracy, sensitivity, and specificity; testing across varied environments. Long-Term Trust Clinicians uncertain about AI predictability, reluctance to rely solely on models. Establish robust feedback channels, leverage medical society standards, and enforce continuous monitoring/refinement. Conclusion and Strategic Roadmap The Bamboo Mindset offers a holistic strategy for the Healthtech sector. The three pillars are intrinsically interconnected: Flexibility, through mechanisms like Agile Compliance and cross-functional teams, enables the rapid adaptation necessary for structural Resilience, particularly in responding to evolving cyber defence mandates. Simultaneously, Steady Growth, founded upon rigorous clinical validation, ensures the long-term trustworthiness and operational integrity that protects and sustains both flexibility and resilience. HealthTech organisations must embrace an ambidextrous strategy, successfully balancing the commercial imperative (profit) with the foundational commitment to patient safety and ethical rigor (purpose). This allows the enterprise to respond dynamically to market forces and regulatory shifts while maintaining an unshakable core strength. The Bamboo Scorecard: Metrics for Measuring Organisational Agility and Trust To measure the strategic maturity of the Bamboo Mindset, a specialized scorecard focused on organizational agility, fortitude, and sustainability is required. 1. Flexibility Metrics Time-to-Compliance (TTC): Measures the institutional speed required to integrate new state privacy laws or revised federal guidelines into the product lifecycle. Cross-Functional Collaboration Index: Quantifies the rate at which regulatory, clinical, and technical issues are flagged and resolved by cross-departmental teams prior to product launch. 2. Resilience Metrics Mean Time to Recovery (MTTR): Measures the speed at which critical clinical systems can be restored following an attack or system failure. Security Posture Compliance: Tracks the rate of universal deployment for mandated security controls, including encryption and Multi-Factor Authentication (MFA). Network Segmentation Integrity: Measures the effectiveness of isolating sensitive ePHI systems, confirming that internal failures or breaches are localised. 3. Steady Growth Metrics Prospective Validation Ratio: The ratio of prospective, multi-site human validation studies compared to retrospective or non-clinical studies used for high-risk device clearance. Post-Market Recall Rate (12-Month Window): Measures the incidence of recalls occurring within the critical first year of market clearance. Clinician Feedback Utilization Rate: Tracks the percentage of structured clinical feedback (on AI performance, usability, and safety) that is formally adopted into algorithm or product refinement cycles. C. Actionable Implementation Guide for the Next 12–24 Months Based on the strategic analysis, the following actions are prescribed to operationalise the Bamboo Mindset: Governance Restructure: Formalise Compliance-Innovation Steering Committees, ensuring legal, clinical, and regulatory experts are integrated into product discovery and development (Flexibility/Growth). This mandates cross-functional input at the earliest stages to leverage anticipatory regulatory strategy. Cybersecurity Investment and Modernisation: Conduct an immediate audit against proposed HIPAA Security Rule updates and allocate capital to finalise all measures that are moving from "addressable" to mandatory. This includes the universal implementation of mandatory encryption, Multi-Factor Authentication (MFA), and robust network segmentation to build structural Resilience. Enhanced AI Validation Standard: Adopt an internal mandate for prospective, multi-site validation studies for all high-risk AI/ML devices, regardless of minimum 510(k) pathway requirements (Steady Growth). This strategic commitment prioritizes patient safety and earned clinical trust over market launch speed, establishing the foundational rigor required for long-term sustainability. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

HealthTech 2026: Disintermediation, Differentiation, Diversification Context and the Maturation of Digital Health (The 2026 Landscape) Shifting Market Dynamics: From Hype to ROI (Discipline and Measurable Outcomes) The HealthTech sector in 2026 is set to transition from a phase of speculative expansion to one defined by maturity, consolidation and fiscal discipline. The operating environment demands strategic clarity, forcing organisations to focus rigourously on demonstrable returns on investment (ROI). This shift is financially evident: digital health funding experienced a significant contraction from its 2021 peak, dropping to just over $10 Billion in 2024. This trend signals market discipline rather than decline, concentrating capital where it can generate verifiable value. The current environment emphasises concentration, evidenced by rising average deal sizes for later-stage companies and a concurrent slump in mega-deals ($100M or more), which now represent only 2% of total deal volume. This financial accountability means the strategic focus has moved from merely "validation" (2025) to achieving immediate "momentum" (2026). Investors and organisational buyers are now enforcing stringent accountability measures, seeking demonstrable, quantifiable value-based metrics for survival. Consequently, procurement standards have tightened considerably. Health systems, payers and employers are no longer interested in piloting experimental tools; they demand seamless integration of proven solutions that align with core operational challenges, such as reimbursement structures and staffing gaps. Solutions must convincingly answer critical viability questions: "Can we bill for it?" and "Does it help us do the work more efficiently?". Furthermore, while consumer health technology remains pervasive, the U.S. wearable health tech market is projected to reach $30 Billion by 2026, pure engagement metrics are now insufficient. The market requires consumer-facing products, including digital therapeutics (DTx), to demonstrate verifiable clinical validity and measurable patient outcomes to secure adoption. The Regulatory Accelerator: CMS, Interoperability, and the Framework for Change Simultaneously, regulatory actions are actively shaping the digital health ecosystem, accelerating structural change. The Centers for Medicare & Medicaid Services (CMS) is strategically leveraging policy to transform data interoperability from a necessary compliance burden into a vital competitive market opportunity. The foundational standard for this change is the HL7 Fast Healthcare Interoperability Resources (FHIR), which enables scalable, API-driven patterns for the secure exchange of health information. The CMS is operationalising this vision through the commitment to create CMS-Aligned Networks and the Q1 2026 projections for patient- and provider-initiated data sharing. By integrating CMS-owned tools, such as the National Provider Directory and Blue Button 2.0 APIs, the U.S. government is building a "reputational and distribution flywheel" for FHIR-native exchange. Participation in these frameworks is now a prerequisite for maximising commercial advantage, accelerating procurement cycles, and building market trust. Crucially, FHIR facilitates secure, granular data access at both the individual patient and population levels. This standardisation is essential for emerging HealthTech entities, often called "apomediaries," to integrate trustworthy information and tools directly into the patient experience without being reliant on fragmented, legacy EHR systems. This increase in data liquidity, supported by regulatory backing, functions as a powerful structural enabler, empowering consumers and strategically accelerating market disruption. Introducing the 3 D's: A Framework for Strategic Navigation The convergence of a disciplined financial market, heightened buyer demands for measurable ROI, and regulatory mandates for digital interoperability creates three dominant strategic pressures for HealthTech as we look ahead into 2026: Disintermediation, Differentiation and Diversification. These are not isolated trends but interconnected forces shaping organisational structure, investment priorities, and competitive advantage. The ability of an entity to navigate this landscape successfully will depend entirely on its mastery of these three D’s. Disintermediation (D1): Eliminating the Middleman and Empowering the Consumer Defining Disintermediation: The Shift to Direct-to-Consumer (DTC) Healthcare Disintermediation is the strategic elimination of intermediary entities between primary market forces, effectively "eliminating the middleman". This powerful, disruptive process has reshaped industries from retail (Amazon) to entertainment (Netflix). Experts contend that healthcare, plagued by complexity, fragmentation, and high costs, is uniquely "ripe for disintermediation". In the healthcare context, this translates into Direct-to-Consumer (DTC) healthcare, where the control and delivery of medical services and products shift directly to the customer, empowering the patient to become the primary driver of decisions. This shift is fundamentally driven by changing consumer expectations. Patients demand better, simpler, and more seamless purchasing experiences, aligning health services with the e-commerce fluidity they encounter in every other aspect of their lives. Digital commerce is the primary catalyst, offering a Software-as-a-Service (SaaS) experience that adheres to regulatory compliance while enhancing accessibility. The immense scale of this transition is underscored by the projection that the global health care e-commerce market will reach $614 Billion by 2026. The Regulatory Catalyst: How 2026 CMS Rule Changes Fuel DTC Care Expansion Federal policy, particularly the proposed 2026 Medicare Physician Fee Schedule (PFS) rules, is actively institutionalising the disintermediation of care delivery. These updates further solidify remote care, specifically Remote Patient Monitoring (RPM) and Remote Therapeutic Monitoring (RTM), as core components of the Medicare delivery model. The proposed changes are strategically designed to remove key friction points that previously limited scalable virtual care. The current structure requires a minimum of 16 days of data recording within a 30-day period for RPM reimbursement (CPT 99454). The proposed introduction of a shorter-duration device code (2 to 15 days) significantly broadens patient eligibility, making RPM models viable for acute and episodic care. Furthermore, the introduction of a proposed 10-minute care management code reduces the current 20-minute threshold for billable time (CPT 99457). This refinement improves clinical flexibility, supporting highly scalable virtual care models and optimising nursing deployment. Crucially, CMS maintains the strategic distinction of RPM/RTM as "care management services," avoiding the stricter originating site and geographic restrictions applied to traditional telehealth. This inherent flexibility provides a competitive advantage for technology solutions focused on chronic disease management outside traditional physical settings, effectively accelerating the strategic shift away from centralised delivery. The regulatory body is using these technical billing codes to actively reshape the market structure, favoring scalable, virtual models. The Rise of Apomediation: Replacing Traditional Intermediaries with Trust Networks The removal of traditional intermediaries, physicians, health plans, or hospitals, does not eliminate the patient’s fundamental need for guidance and trust. This strategic void is filled by apomediation. When established gatekeepers are bypassed, the consumer still requires tools and peer networks to validate information and establish credibility. Apomediaries are defined as influential peers, community opinion leaders, and digital tools that guide consumers to trustworthy information. For this model to succeed, the consumer must achieve a level of autonomy and maturity, becoming a co-creator of content rather than a passive audience. This realisation requires HealthTech developers to build solutions based on community and social credibility (often leveraging Web 2.0 or 3.0 models) rather than merely broadcasting information. The success of pure DTC models, which shift control entirely to the patient, relies on these sophisticated apomediary structures to provide the necessary structure and digital trust to replace the clinical authority of the professional middleman. In this networked environment, the credibility of the apomediary tool or peer can become equally, or more, important than the credibility of the original source. Market Impact: The Commoditisation Risk for Traditional Incumbents The structural pressure of Disintermediation places immense strain on legacy health systems. These incumbents face an acute risk of their core services being commoditised and their mission jeopardised by "well capitalised new competitors: health plans, private equity, retail and big tech". The influx of deep capital from these non-traditional entrants has essentially erased the traditional organisational "swim lanes". A prime manifestation of this threat is the rapid expansion of the "Payvider" model. Large health plans are strategically expanding into managing health care costs and outcomes directly, moving beyond their traditional role as benefits managers. This vertical diversification is substantially fuelled by the financial attractiveness of government programs, such as Medicare Advantage (MA), where over 50% of beneficiaries are in efficient HMO products. This aggressive vertical shift by payers directly disintermediates traditional fee-for-service providers, forcing legacy systems to immediately address their core value proposition. Differentiation (D2): Achieving Distinct Value through Hyper-Personalization The Necessity of Differentiation in a Concentrated Market In the newly disintermediated landscape, Differentiation is not merely a marketing tactic but a competitive imperative. As commoditisation risk rises, establishing a Unique Value Proposition (UVP) becomes the cornerstone of survival. The UVP must precisely articulate the distinctive combination of what is offered, how it is delivered, and why it matters to the specific client base. The tight capital environment of 2026 mandates specialisation in high-value, outcome-driven areas. Market buyers, including employers and health systems, are enforcing a "less is more" strategy, prioritising quality solutions that yield measurable financial ROI over a large quantity of unproven tools. Specialty care, for instance, represents a high-leverage focus area, accounting for 50% of an employer’s health spend and growing faster than pharmacy spend. Consequently, successful startups are those that align their differentiation strategies with clear institutional priorities: access, affordability, and accountability. This includes specialised, device-agnostic RPM platforms, digital mental health solutions targeting value-based care populations, and specialized care enablers. Specialisation against high-cost, high-acuity niches provides a protective barrier against generalist competitors and is the primary defence against the systemic pressure of commoditisation. The Core Strategy: AI-Powered Hyper-Personalisation The mechanism for achieving sustained Differentiation is hyper-personalisation, driven by advanced technological capabilities. Modern patients now expect the seamless, tailored experiences common in consumer sectors, such as "Amazon-style recommendations and Netflix-driven content curation". This heightened expectation renders traditional mass-marketing and segmentation models obsolete. Hyper-personalisation is defined as deep 1:1 tailoring across every touchpoint, ensuring that each interaction, from insurance communications to provider portals, is unique to the individual. The goal is to make patients feel genuinely understood and valued, treating them as people rather than organisational statistics. This depth of tailoring drives core organisational benefits, including increased patient loyalty and trust, better health outcomes via timely, relevant reminders, and enhanced operational efficiency achieved by eliminating wasted spend on generic content. Generative AI as the Engine of Scale and Precision Generative AI (GenAI) is transforming hyper-personalisation from a creative ideal into a scalable reality. GenAI allows organisations, particularly in life sciences, to automatically generate highly tailored content, such as personalised product descriptions or communications, at a scale and speed previously impossible. This ability to craft unique messaging based on browsing history and preferences enables rapid speed-to-market for effective, real-time personalisation. In clinical settings, GenAI facilitates significant Differentiation by analysing comprehensive patient data (medical history, genetics, real-time health metrics) to create customised treatment plans. It supports personalised patient education and powers virtual health assistants available 24/7. The ability of GenAI to use "Unified Patient Insights" derived from comprehensive data sets (EHR activity, digital behaviours) to craft 1:1 communications demonstrates precision paired with compassion, thereby establishing the crucial trust and loyalty necessary for engaging patients in complex digital care pathways. However, the implementation of GenAI requires hyper-caution, given the potential for "hallucinations" and the sensitivity of health data. Strong governance, often established through a Center of Excellence model, is necessary to centralise expertise, manage bias, and ensure ethical application of AI, particularly in areas like continuous professional development for health workers and precision medicine. Strategically, the dominant adoption model for GenAI is through partnerships with third-party vendors and hyperscalers, leveraging their expertise in cloud infrastructure and data management rather than relying on costly in-house development. Diversification (D3): Expanding Strategic Footprints Defining Diversification in Healthcare Diversification represents a strategic mandate for organisations seeking strong profit growth and access to higher-value revenue streams, particularly when their core businesses face market headwinds. This strategy is essential for achieving financial resilience. Successful diversification must target areas that maintain a natural synergy with the organisation’s existing core assets, such as distribution networks, data repositories, or customer bases. The trend is amplified by the entry of powerful new entrants from non-health industries, compelling incumbents to broaden their strategic footprint. Strategic Models of Diversification Diversification typically follows two structural paths: vertical integration and horizontal expansion into adjacent services. Vertical Integration Vertical acquisitions involve integrating different stages of the healthcare value chain, such as a payer acquiring providers (the Payvider model) or a system establishing its own pharmacy management service. Benefits include the diversification of revenue streams, enhanced quality and operational efficiency through integrated stages, and cost reduction by eliminating reliance on third-party suppliers, which essentially internalises the process of Disintermediation. While previous integration efforts were sometimes driven by governmental uniform pricing, modern vertical models focus on better coordinating managed care and aligning physician and hospital financial risks for superior performance. Horizontal/Adjacent Services Expansion Horizontal diversification involves expanding into non-traditional or technology-enabled adjacent services. This strategy leverages technologies like telehealth, Remote Patient Monitoring (RPM), and hospital-at-home models to deliver care in ways consumers prefer, often resulting in lower costs or improved accessibility. Examples include partnerships where technology companies and healthcare entities collaborate, such as Best Buy diversifying into homecare services through external partnerships. CVS Health, for instance, focuses on strategic growth in health services and primary care, leveraging its unique combination of retail, payer, and PBM assets to capture a greater share of healthcare spend. However, organisations must be acutely aware that Diversification carries significant risk; initiatives unrelated to core capabilities, such as Walmart’s foray into healthcare delivery, have demonstrated a failure to achieve competitive viability because they were misaligned with core competencies, failing Michael Porter’s essential tests of corporate strategy. The Big Tech Factor: Diversification as an Intellectual Monopoly Strategy The most significant driver of Diversification is the strategic entry of Big Tech giants (Amazon, Google/Alphabet, Apple, and Microsoft). Their expansion into healthcare is systematically driven by their existing data-driven intellectual monopoly power and an objective to acquire new data and knowledge to sustain that monopoly. These companies are responding to the fundamental market shift where patients and professionals increasingly rely on technological products to access and analyse health data. For these giants, diversification (D3) is an offensive strategy aimed directly at mass Disintermediation (D1). They utilise superior resources, such as Google’s expertise in data analytics and AI/DeepMind, or Apple’s consumer trust and massive device ecosystem, to bypass traditional infrastructure. Microsoft, for instance, leverages its enterprise IT position to become the trusted leader in healthcare IT, driving GenAI partnerships and EHR integration. A key evolution in this strategy is the prominence of partnerships. Big Tech frequently collaborates with healthcare institutions to access the necessary health data required to develop clinically relevant solutions. GenAI adoption, similarly, is dominated by partnerships with hyperscalers. This preference for complex, aligned partnerships over outright acquisition allows Big Tech and innovators to access crucial expertise, patient data,and distribution channels without the massive capital risk and misalignment issues associated with unrelated full vertical integration. The Convergence of the 3 D's: A Systemic Analysis The forces of Disintermediation, Differentiation, and Diversification do not operate sequentially but in a highly dynamic feedback loop, creating compounded pressure and accelerating market change. The Interplay: How Disintermediation Drives the Need for Differentiation The shift of control to the consumer, inherent in Disintermediation (D1), instantly raises the competitive stakes. Empowered patients will elect to "depart from service providers that don't meet expectations". This newfound consumer autonomy makes institutional loyalty tenuous and compels every organisation to achieve genuine Differentiation (D2). D1 strips away the protection of historical market position; D2 provides the competitive edge, whether through hyper-personalisation, specialisation in high-ROI fields, or superior user experience, required to win and retain the autonomous consumer. The Foundational Driver: Interoperability (FHIR) Connecting the Three Forces The technical infrastructure underlying this strategic convergence is the robust adoption of FHIR. FHIR is the essential data plumbing that translates regulatory impetus into commercial capability across all three vectors. Enabling D1: FHIR ensures that data can be accessed securely at the patient level via APIs.This reliable data liquidity is vital for DTC models to function safely, allowing the consumer to retrieve and share their information without relying on the physical institution (the bypassed intermediary). Enabling D2: The ability to gather and standardise diverse datasets consistently, as FHIR resources allow, is the prerequisite for scaling GenAI and hyper-personalisation. Without FHIR’s structured data exchange, achieving the granular "Unified Patient Insights" necessary for 1:1 tailoring is technically infeasible. Enabling D3: FHIR facilitates the seamless integration required for large-scale vertical and horizontal expansion. For Big Tech or diversifying health systems, FHIR makes it easier to integrate new services or access institutional data, streamlining the expansion process. Investment in FHIR, therefore, represents a strategic investment in resilience across all three domains. Strategic Feedback Loop: How Diversification Enables Disintermediation The cycle concludes as successful Diversification (D3) acts as an offensive strategy to achieve systemic Disintermediation (D1). When organisations, particularly Big Tech, successfully diversify by leveraging data and logistics, they gain the necessary assets to construct new care delivery models that inherently bypass legacy structures. Furthermore, the operational speed of D1 and D3 expansion, coupled with the inherent complexities of health data regulation, necessitates robust RegTech adoption. RegTech, focused on compliance automation, risk management, and data governance, is now a critical strategic requirement. It allows organizations to match the pace of technological innovation without incurring catastrophic regulatory risks, serving as a strategic enabler for agile expansion in a rapidly changing environment. The Interconnected 3 D’s Framework (2026 Strategic Dynamics) Driving Force Mechanism of Action Strategic Outcome Core Technology Enabler Disintermediation (D1) Shifting control to the consumer (DTC) and eliminating the middleman. Commoditization of undifferentiated, centralised services. Regulatory shifts (RPM/RTM rules) and E-commerce SaaS experience. Differentiation (D2) Achieving distinct value through hyper-personalization and specialization. Improved consumer trust, measurable health outcomes, and competitive advantage. Generative AI, Real-time Data Analytics, Unified Patient Insights. Diversification (D3) Expanding core business into adjacent, synergistic, high-value profit pools. New revenue streams, resilient financial performance, and offensive market entry. Partnerships with hyperscalers, Vertical/Horizontal Integration, Data Monopoly Exploitation. Strategic Imperatives and Conclusions The HealthTech market in 2026 is defined by these three interconnected strategic forces. To ensure financial viability and market relevance, stakeholders must adopt tailored strategies that treat the 3 D’s as a cohesive framework. Strategic Imperatives for Incumbents Legacy health systems and payers must embrace an offensive Diversification strategy (D3). This involves actively launching new technology-enabled services (e.g., hospital-at-home, integrated virtual care) that align with evolving consumer preferences and create new profit pools. Internally, organisations must manage their own Disintermediation (D1) by proactively shifting care delivery to lower-cost, alternative sites and maximising technology for efficiency. Crucially, they must treat FHIR adoption as a commercial accelerator, leveraging data exchange efficiency to gain competitive advantage in procurement and partnership negotiations. Strategic Imperatives for Innovators HealthTech innovators and startups must prioritise Differentiation (D2) through specialization. Success is contingent upon developing condition-specific, device-agnostic platforms focused on high-ROI niches (e.g., RPM for chronic disease or specialised mental health solutions) where favourable reimbursement is established. Consumer-facing products must move beyond engagement metrics to demonstrate "clinical teeth," focusing on clear, verifiable clinical and financial outcomes to meet rigorous buyer demands. For Diversification (D3), smaller innovators should prioritize early partnerships with established health systems or large industry players to secure validation and distribution, mitigating reliance on a volatile venture capital market. Conclusions: The Path to Resilience The 2026 HealthTech environment mandates a shift from broad experimentation to specialised, outcome-driven execution. The strategic necessity of Differentiation (D2) arises directly from the systemic threat of Disintermediation (D1), while targeted Diversification (D3), particularly by Big Tech, acts as the primary engine driving D1. The successful navigation of this dynamic framework requires foundational investments in FHIR interoperability and robust ethical GenAI governance. Organizations that centralize expertise and adopt transparent, high-trust hyper-personalisation strategies will be positioned to secure loyalty, enhance outcomes, and achieve sustainable competitive advantage in the mature digital health market. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk   Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @   https://www.healthcare.digital     We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb     Founders for Founders >  We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk   #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #BuySide   #SellSide #Divestitures   #Corporate   #Portfolio   #Optimisation   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech   Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk   Meet Us @ HealthTech events   Digital Health Rewired > 18-19th March 2025 > Birmingham, UK  NHS ConfedExpo   >  11-12th June 2025 > Manchester, UK  HLTH Europe >  16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate >  25th June 2025, London, UK  HIMSS AI in Healthcare  >  10-11th July 2025, New York, USA Bits & Pretzels >  29th Sept-1st Oct 2025, Munich, Germany   World Health Summit 2025  >  October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit >  October 16th 2025, London, UK  HLTH USA 2025 >  October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 >  10th-13th November 2025, Lisbon, Portugal   MEDICA 2025 >  November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America.  www.nelsonadvisors.co.uk

Executive Summary: The Selective Stress Test – Resilience Amidst Point Fatigue The European HealthTech ecosystem is undergoing an accelerated Strategic Maturation Stress Test.This phase is characterised by intense, localised friction points, acute clinical fatigue among providers stemming from friction-laden Electronic Health Record (EHR) systems and operational pressure on developers navigating regulatory complexity. Crucially, these pressures are not causing widespread collapse but are acting as powerful catalysts, enforcing market cleanup and consolidation. The resilience of the European sector is confirmed by several key factors: robust H1 2025 funding which defied global declines, the legislative implementation of mandatory interoperability standards through the European Health Data Space (EHDS) and a pronounced investor flight to quality. Capital is selectively channelled towards high-quality assets, specifically clinically validated Artificial Intelligence (AI) and Value-Based Care (VBC) solutions. The most significant immediate consequence of this stress test is the surge in Mergers & Acquisitions (M&A) activity, particularly private equity-driven "roll-up" strategies designed to achieve necessary scale and efficiency. The market is demanding maturity, shifting focus from speculative growth to demonstrable profitability and integrated utility. Defining the Tripartite Risk: Digital Fatigue in European HealthTech Conceptual Framework: Distinguishing Fatigue from Market Maturation Digital fatigue in a technological ecosystem is conceptually defined as a critical loss of efficacy, trust and sustained momentum across key stakeholder groups. It manifests as deep cynicism among healthcare providers (HCPs), rapid disengagement and churn among end-users (patients), or market stagnation driven by excessive friction for developers and investors. The assessment of the European HealthTech sector ending 2025 requires distinguishing this paralysing fatigue from the inevitable turbulence associated with market maturation. The current environment is defined by the simultaneous implementation of foundational EU policies, such as the EHDS and the AI Act, coupled with macroeconomic headwinds, including rising interest rates and increased capital costs throughout late 2024 and early 2025. These combined elements have profoundly elevated the financial and operational hurdle rate for HealthTech ventures, compelling a strategic shift where investors mandate profitability and stable growth over aggressive expansion. The combination of funding selectivity and escalating regulatory compliance costs creates substantial pressure, particularly on early-stage or non-validated firms. If the market were truly fatigued, investment and innovation would uniformly retract. The observed trend, however, is a redirection of capital toward demonstrably efficient and high-quality assets, specifically those leveraging AI and advanced analytics. This sustained, yet highly discerning, investment pattern is diagnostic of a resilient ecosystem undergoing a stress test, whereby market forces and regulatory clarity act as necessary mechanisms to purge unsustainable, fragmented solutions, thereby strengthening the foundation for long-term growth. The Three Vectors of Digital Fatigue The potential for systemic digital fatigue is analysed through three interconnected vectors, each representing a distinct stakeholder group and point of failure: Clinical Fatigue (Provider Burnout): This vector is defined by the significant gap between the anticipated transformative promise of digital tools and the often disappointing operational reality experienced by healthcare professionals. It encompasses frustration arising from cumbersome user interfaces, increased administrative overhead, and cognitive load. User Fatigue (Adherence Crisis): This refers to the structural weakness observed in software-based interventions, particularly Digital Therapeutics (DTx), characterised by low patient retention rates and inconsistent, short-term engagement over the long term. Ecosystem/Developer Fatigue (Regulatory Drag): This vector relates to the high friction, complexity, and disproportionate compliance costs associated with navigating the simultaneous, and occasionally overlapping, implementation of major EU regulations, including the EHDS, the AI Act, and the Medical Devices Regulation (MDR)/In Vitro Diagnostic Medical Devices Regulation (IVDR). Clinical Exhaustion and the Productivity Deficit (The Provider Vector) Quantifying the Expectation Gap: Optimism vs. Utility in 2025 While the long-term vision for digital transformation remains strong, current practical application shows significant weaknesses, creating an "expectation gap" that defines the scope of clinical fatigue. Data from a 2025 BMJ Future Health Commission survey indicates that three-quarters of healthcare professionals (76%) maintain optimism regarding the future of digital transformation, with 80% believing digital tools have enabled better care delivery. However, this high level of optimism dissolves when professionals assess the immediate, practical impact on their workflow. Less than half (47%) of HCPs report that the introduction of digital technology has actually eased administrative tasks. Furthermore, a significantly smaller minority, just 38%, state that digital technology has resulted in a reduced clinical workload. Additionally, only 44% of HCPs believe that digital technology has contributed to decreasing the cost of delivering healthcare. This wide disparity between 76% optimism and 38% realised workload reduction is highly precarious and unsustainable. This expectation gap strongly suggests that while the solutions themselves may hold inherent value, they are being implemented within inadequate, non-integrated clinical workflows. If this gap is not substantially narrowed in the near term (2026-2027), the existing goodwill and optimism will inevitably deteriorate into deep-seated cynicism and technology resistance, culminating in a state of full, debilitating clinical fatigue across the workforce. The EHR Paradox: High Adoption, High Frustration A primary source of clinical fatigue originates from poor experiences with Electronic Health Record (EHR) systems, which are the most broadly adopted clinical technologies. The friction generated by these systems is actively undermining overall trust in the promise of all digital health initiatives. The data confirms this challenge: healthcare professionals who frequently interact with EHRs are 14 percentage points less likely than non-users to believe that digital solutions reduce administrative burden or ease clinical staff workload. Poor user experience with EHRs, which are often perceived as cumbersome and regulatory compliance tools rather than efficiency drivers, establishes a negative conditioning effect. This inherited skepticism from foundational, frustrating legacy systems acts as an inertial drag on the adoption of all new, transformative technologies, such as predictive analytics or advanced remote monitoring solutions. Consequently, the immediate strategic focus for organisations seeking to advance digitalisation must shift from simply deploying new point solutions to fixing the underlying foundational infrastructure and addressing interoperability deficits. This systemic inertia must be overcome before new technologies can gain genuine acceptance. Poor interoperability, the inability of diverse computer systems to seamlessly exchange and use information, is explicitly cited by HCPs as the second-highest barrier to adoption, trailing only funding constraints. Addressing interoperability is crucial to resolving the systemic friction that currently fuels clinical burnout. Cognitive Overload: The Specific Risk of Alert Fatigue Localized, operational fatigue also manifests as specific phenomena like "alert fatigue." General Practitioners (GPs) are increasingly experiencing this due to constant Clinical Reminders (CRs) generated by sophisticated electronic systems. The growing complexity of medical knowledge and data management systems increases the cognitive load placed on GPs, leading to over-alerting. The severe consequence of this overload is "chronic negligence", a tendency for GPs to disregard pertinent or urgent CRs, potentially compromising patient safety and the quality of care delivered. A systematic review using the NASSS framework suggests that overcoming this issue requires close collaboration with GPs on system design, undertaking organisational-level training on utility and benefits, and ensuring contextual nuance in the design of alerts. Clinical Fatigue Indicators (The Expectation Gap - 2025) Indicator HCP Sentiment Context / Impact Optimism about Digital Future 76% (High) Reflects belief in potential, but contrasts sharply with experienced benefits. Belief Digital Eased Administrative Tasks 47% (Low) Less than half feel operational relief, suggesting poorly integrated workflows. Belief Digital Reduced Clinical Workload 38% (Very Low) Core indicator of failed promise; fuels cynicism and burnout. Trust in Digital Health Technologies 59% (Moderate) Significant hesitancy (41%) requires focused effort on building 'Operational Trust'. EHR Users Less Likely to See Admin Relief 14 percentage points Previous negative experiences (EHRs) act as a barrier to adopting other transformative tools. Mitigation Imperatives: Trust, Training, and Co-Design Widespread adoption of Digital Health Technologies (DHTs) by the workforce has been slow, facing multifaceted barriers related to infrastructure, time, increased workload, and insufficient training. To overcome these adoption challenges, experts emphasise the need for a targeted approach centred on trust and involvement. To realise the promised benefits, healthcare organisations must focus on two types of trust: Foundational Trust (rigorous, transparent standards and regulation) and Operational Trust (ensuring frontline clinicians actively help design, select, and receive training on certified tools). Significantly, nearly two-thirds (61%) of healthcare professionals identify an opportunity to increase their participation in technology investment decisions. Furthermore, enhanced training is seen as the single most valuable factor for effective implementation, capable of supporting up to 45% of clinicians and 43% of non-clinical workers in building necessary confidence and capability in digital tools. The Adherence Chasm: Patient Fatigue and Digital Therapeutics (DTx) (The User Vector) Challenges in Long-Term Patient Engagement and Retention The effectiveness of digital health solutions is critically dependent on sustained patient interaction. Patient engagement and retention remain key challenges across the sector, as many users fail to consistently engage with digital health solutions beyond initial adoption. This issue is particularly structural for Digital Therapeutics (DTx), which are software-based interventions designed to manage, prevent, or treat conditions. Despite this systemic weakness, the European Digital Therapeutics Market is projected to exhibit robust expansion, anticipating a Compound Annual Growth Rate (CAGR) of 21.83% from 2025 to 2034. Sustaining this exponential growth is conditional upon resolving the long-term retention problem. Unlike physical devices, DTx solutions rely on continuous user input to generate the clinical evidence required for regulatory approval and to demonstrate the quantifiable cost savings necessary for insurer reimbursement. If patient adherence rates are consistently low, the clinical evidence base necessary for validation crumbles, which in turn undermines the financial viability and return on investment (ROI) sought by investors. Therefore, patient fatigue represents a direct threat to the financial stability and scalability of the DTx sub-sector. Regulatory and Sociodemographic Barriers to Adoption The adoption of DTx varies significantly across Europe. This inconsistency is primarily attributable to a lack of harmonised regulatory requirements and disparate reimbursement mechanisms across the continent, despite countries sharing similar general approaches to digital health. This fragmentation inhibits the cross-border scaling necessary for achieving high investor returns. Furthermore, sociodemographic factors introduce critical barriers to widespread, consistent adoption. Disparities in digital literacy and healthcare access, particularly pronounced in rural and economically disadvantaged regions, limit the ability of digital therapeutics to reach and effectively serve all target populations. To overcome these challenges, national and regional digital health initiatives must be guided by robust strategies that integrate digital tools into broader societal goals, such as improving integrated long-term care (I-LTC) and enhancing societal well-being. Leveraging Value-Based Care Models to Drive Sustained Use European healthcare systems are fundamentally shifting from a volume-based (fee-for-service) model to one centred on value-based care (VBC). This strategic realignment favors preventative digital platforms that reduce the risk of chronic disease onset or delay progression, such as tools for weight management or cardiovascular disease prevention. This systemic shift provides an economic mechanism to mitigate patient fatigue. By tying financial incentives (and thus reimbursement) directly to positive health outcomes rather than merely the volume of service provided, VBC compels providers and payers to actively monitor and improve patient retention and adherence metrics. Companies that successfully enable this transition to VBC, by providing solutions that deliver measurable cost savings and improved patient outcomes, are commanding premium valuations in the market. This alignment shifts the entire focus of solution providers from simple distribution to ensuring sustained, high-quality patient engagement. Regulatory Overload: The Developer Fatigue Vector The European Health Data Space (EHDS): Mandatory Interoperability and Compliance Burden The single most consequential regulatory development in 2025 is the European Health Data Space (EHDS) Regulation, which formally entered into force on March 26, 2025.The EHDS significantly enhances patients' rights to access and manage their health data and, crucially, imposes mandatory interoperability standards for Electronic Health Records (EHR) systems. The scope of the EHDS is expansive, applying to a broad range of stakeholders, including healthcare providers, EHR system manufacturers, digital health companies, and any entity processing health data within the EU. Although the provisions governing secondary use of health data will not become applicable until 2029, companies must initiate immediate, substantial adaptation efforts. Noncompliance exposes businesses to significant financial penalties and potential restrictions on market access. While the EHDS compliance journey is resource-intensive, it strategically addresses the core interoperability barrier cited by clinicians as a major source of friction. For well-capitalised firms, this heavy initial compliance burden functions as a "strategic moat," significantly raising the barrier to entry for smaller, less robust competitors. This process is rewarding firms that invest in robust data governance and interoperability capabilities with higher valuation multiples, thereby driving market cleanup. Navigating Dual Compliance: The AI Act and Medical Device Regulations (MDR/IVDR) The European regulatory landscape is further complicated by the concurrent deployment of the Artificial Intelligence (AI) Act, which entered into force in August 2024, with obligations for General Purpose AI (GPAI) and governance rules becoming applicable in August 2025. This horizontal framework creates a significant overlap for medical technology, as high-risk AI systems used in diagnostics and treatment are already stringently regulated under the existing Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR). MedTech Europe has articulated concerns that applying these two complex product frameworks in parallel, without sufficient regulatory harmonisation, threatens to delay patient access to life-saving technologies and create unnecessary regulatory bottlenecks. Implementation challenges include unclear guidance for specific technologies, difficulties ensuring fairness across diverse patient populations, and inconsistent implementation across varying EU countries. The uncertainty surrounding these frameworks results in a resource allocation deficit: companies are forced to divert technical and financial resources away from core research and development (innovation velocity) and toward documentation and quality management systems (QMS) requirements. This regulatory friction occurs precisely when investors are simultaneously demanding increased technical complexity (AI integration) and rigorous clinical validation. To mitigate this friction, MedTech Europe has called on policymakers to extend the application date for AI systems covered by MDR/IVDR until August 2029, allowing essential guidance and harmonised standards to be finalized. The Financial Cost of Compliance: Impact on SMEs and Market Concentration The costs associated with regulatory compliance, particularly for MDR/IVDR, are substantial and act as a powerful catalyst for consolidation. Survey data indicates that compliance costs are heavily skewed toward personnel, with 90% of expenditures dedicated to Quality Management System (QMS) and Technical Documentation (TD) processes. Furthermore, maintenance and re-certification costs are projected to exceed initial certification fees significantly. These non-scalable fixed costs, combined with the inherent complexity of navigating dual compliance mandates, disproportionately affect Small and Medium Enterprises (SMEs), which constitute 90% of the over 38,000 companies in the European MedTech sector. This financial strain creates intense developer fatigue among smaller firms. This challenging environment, however, drives consolidation, favoring strategic buyers and Private Equity (PE) firms who can achieve operational efficiencies by centralising compliance functions and scaling QMS processes across multiple portfolio acquisitions. In this context, developer fatigue effectively transforms regulatory compliance from a mere barrier into a central pillar of market maturity and strategic M&A activity. Market Dynamics: Stressors and Strategic Resilience (Year-End 2025) (The Investor Vector) The 2025 Funding Recalibration: From Growth to Selective Scale Investor behaviour in 2025 confirms the ongoing maturation stress test, showcasing a bifurcated market response to global economic pressures. Despite global digital health funding declining by 11% year-on-year, European Digital Health funding demonstrated remarkable resilience in the first half of 2025 (H1), surging 52% year-on-year to reach $3.4 Billion across 182 deals. This impressive performance allowed Europe to capture a record 26% share of global funding, defying the general market recalibration. However, this resilience was immediately tested in the third quarter (Q3) of 2025. Initial data for Q3 2025 indicates a significant market adjustment and slowdown. August funding recorded only $73 million, a sharp 76% decrease from July's $298 million. Deal volume similarly plummeted, falling 84% from 19 deals in July to only 3 in August. Furthermore, early-stage companies experienced a steep decline in capital access, raising $647 million in the first seven months of 2025, down from $1.4 billion during the same period in 2024. This heightened selectivity is also evidenced by the stretching of average early-stage funding intervals to 25.7 months. This extreme volatility, an H1 boom followed by a sharp Q3 correction—is not indicative of systemic fatigue, but rather a profound market bifurcation. Investor behavior is "increasingly selective", prioritising companies with proven impact, demonstrable clear outcomes, and a focus on profitability and stable growth. Speculative or non-validated ventures suffer immediate investor fatigue, evidenced by the Q3 slowdown. Conversely, mature, high-quality companies continue to attract premium valuations, establishing a robust "selective scale" model that enhances the ecosystem's overall quality threshold. European HealthTech H1-Q3 2025 Funding Metrics Metric H1 2025 Performance Q3 2025 Initial Trend Implication Total Funding (H1 vs H1 YoY) $3.4 Billion (+52%) Significant month-on-month slowdown (Aug $73M vs Jul $298M) H1 surge defies global trend, but Q3 signals sharp selectivity/ recalibration. Share of Global Funding Record 26% N/A Europe’s strategic importance and resilience increasing relative to US. Early-Stage Funding (Jan-Jul 2025) $647 Million (Down from $1.4B in 2024) Deal activity plummeted (3 deals in August) Acute investor fatigue in speculative, early-stage deals; flight to quality. Average Early-Stage Funding Interval 25.7 months N/A Capital access is harder and slower, confirming profitability mandate. AI and Analytics: The Primary Magnet for Resilience and Premium Valuation The demand for solutions that drive efficiency and measurable outcomes has made Artificial Intelligence (AI) the single greatest driver of valuation premiums in the HealthTech sector. Investors are focusing heavily on companies with proprietary AI algorithms, clinically validated solutions, and deep integration into established healthcare workflows. The market recognises this strategic importance through high multiples. Premium segment companies specialising in AI, scalable telehealth platforms, and advanced analytics are commanding premium valuations, typically ranging from 6x to 8x revenue or more. Companies that align with the shift toward Value-Based Care (VBC) and provide demonstrable cost savings and improved patient outcomes are also highly sought after, with revenue multiples climbing to 5.5x to 7x. Investment concentration reflects this strategic focus, with most deals falling into Medical Diagnostics, Health Management Solutions, and Wellness clusters, all with a clear mandate for AI integration. While Oncology and Cardiovascular diseases remain dominant funding recipients, Geriatrics realized the greatest percentage growth in H1 2025, growing a staggering 2126% quarter-on-quarter, demonstrating an acute response to demographic imperatives. M&A and Consolidation: The Role of Private Equity in Market Maturity M&A remains the dominant pathway for exits by volume, accounting for 107 of 113 total digital health exits globally in H1 2025. The broader IPO market is projected to remain subdued throughout the remainder of 2025, presenting a continued challenge for larger private equity-backed firms seeking public listings. In response to this challenging exit environment, Private Equity (PE) firms have become key drivers of market maturity and consolidation. The number of sponsor buyout deals in European healthcare spiked by a substantial 276% year-to-date in June 2025 compared to the same period in 2024. PE firms are aggressively executing "roll-up" strategies, investing in tech startups to acquire smaller rivals and consolidate fragmented point solutions into dominant conglomerates. These firms are injecting technology, particularly AI, into acquired businesses to drive efficiency and margin improvements. This financial engineering stabilises the market by offering essential liquidity (an alternative to traditional IPOs) and ensuring that capital deployed during the earlier, more speculative phases can realize returns through strategic integration, thus mitigating broad investor fatigue induced by challenging public markets. Strategic Verdict and Outlook: Proximity to Systemic Fatigue Synthesis of Risk Factors: Where Fatigue is Most Acute Digital fatigue is not a state of systemic failure in European HealthTech but is acutely concentrated at the interfaces of high organisational and operational friction: Interface Fatigue (Clinical): This is highly acute among frontline staff forced to interact with poorly designed and non-interoperable EHR systems that actively increase administrative and clinical workload. This compromises the adoption of otherwise beneficial, high-potential tools. Compliance Fatigue (Developer): This is most acutely felt by Small and Medium Enterprises (SMEs) struggling to navigate the complex, resource-intensive dual regulatory frameworks established by the AI Act and the existing Medical Device Regulations. This compliance burden stresses balance sheets and extends time-to-market. Retention Fatigue (User/Investor): This is a chronic vulnerability, particularly within the DTx sector, where a persistent inability to guarantee sustained patient adherence threatens the clinical efficacy and long-term financial viability required for market scale. Evidence of Systemic Resilience: Policy Drivers and Smart Capital Flow The overall ecosystem is demonstrating systemic resilience, underpinned by decisive policy action and capital discipline. EU policies, notably the EHDS and the Digital Decade Programme, are enforcing a transition toward integrated, interoperable digital infrastructure. The composite eHealth maturity score for the EU-27 reached an average of 83% in 2024, demonstrating consistent progress toward the 2030 target. Investor confidence is characterised by discernment. Capital is increasingly channeled only to companies that possess clinically validated datasets, clear reimbursement pathways, and robust, defensible AI intellectual property. Analyst consensus characterizes the market as exhibiting "remarkable resilience" and a "cautious yet discernible rebound", driven fundamentally by a mature focus on profitability and proven business models over speculative expansion. 2026 Forecast: A Transition from Fragmented Solutions to Integrated Infrastructure The European HealthTech market, valued at an estimated $96.68 Billion in 2025, is firmly transitioning from fragmented early experimentation to scalable, proven models integrated into critical healthcare infrastructure. Accelerated deal activity is strongly anticipated in the latter half of 2025 and into 2026, driven by intensified competition between strategic buyers and Private Equity firms vying for high-quality assets. AI solutions are transforming from experimental concepts into critical, scalable infrastructure components, which is expected to continue attracting significant investment. The core strategic dynamic observed is that the current clinical fatigue, caused by non-interoperable and cumbersome legacy systems, serves as the most powerful practical and political justification for the EHDS mandate. Therefore, the localised fatigue experienced today is paradoxically the necessary precursor and financial rationale for the large-scale, long-term infrastructure investment required to achieve the next phase of sustainable, high-utility growth in European HealthTech. Strategic Recommendations Recommendations for Healthcare Providers (Mitigating Clinical Fatigue) Prioritise Trust Building: Healthcare organizations should immediately implement measures to build "Operational Trust," ensuring that frontline HCPs are actively involved in the design, selection, and implementation of new technology platforms, as defined in major industry reports. Mandate Interoperability Compliance: Leverage the enforcement of the EHDS Regulation to accelerate internal compliance and procurement policies. Prioritise vendor solutions that demonstrate native interoperability and seamless integration with existing EHRs over fragmented, standalone applications, directly addressing the primary cause of clinical workflow friction. Targeted Training Investment: Commit to sustained, long-term staff training programs designed to enhance digital literacy and capability, recognising that insufficient training is a primary structural barrier to successful technology adoption and usage. Recommendations for HealthTech Developers (Navigating Regulatory Complexity) Adopt Compliance by Design: Embed multi-layered regulatory requirements (EHDS, AI Act, MDR/IVDR) into the product roadmap from the earliest stages of development. Focus investments on achieving rigorous clinical validation and robust data governance frameworks to position the company for premium investor multiples. Focus on Integration, Not Isolation: Design solutions that are natively interoperable with established healthcare workflows and infrastructure, particularly EHR systems, to directly mitigate the primary driver of clinical fatigue: workflow friction. Validate Adherence as an Outcome: For DTx and patient engagement platforms, incorporate advanced behavioral science and user-centric design principles specifically engineered to maximize long-term patient engagement and retention. Provide demonstrable metrics of adherence to prove long-term ROI to prospective payers and investors. Recommendations for Investors and Policy Makers (Sustaining Selective Growth) Investment Strategy: De-risk future capital deployment by exclusively focusing on companies that provide measurable cost savings (VBC alignment), possess proprietary, defensible AI intellectual property, and demonstrate clear commitment to achieving and maintaining stringent EU regulatory standards. Exit Strategy: For the immediate future, prioritise and plan primary exit pathways through strategic M&A or Private Equity "roll-ups," given the established prevalence of these transactions and the projected continued caution in the broader IPO market throughout 2025. Policy Support: Policymakers should urgently address the innovation friction caused by regulatory overlap. This requires expediting the necessary guidance and harmonization between the AI Act and the MDR/IVDR to ensure the continued, safe development of critical high-risk AI systems, potentially by adopting the industry recommendation for extended transition periods. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Who are the leading Digital Health M&A Advisors in Europe? Executive Summary: The Bimodal Strategy in European Digital Health M&A The advisory landscape supporting Mergers and Acquisitions (M&A) within the European Digital Health sector is highly structured and complex, reflecting both the rapid technological evolution of the industry and the strategic consolidation imperatives driving its participants. A comprehensive analysis demonstrates that a singular definition of a "leading" advisor is insufficient. Instead, the market is fundamentally characterised by a bimodal distribution of influence. This distribution features two dominant, distinct classes of advisory firms. The first class comprises Global Financial Powerhouses, typically Bulge Bracket or large full-service institutions, whose leadership is derived from their capacity to execute large-cap, multi-jurisdictional transactions and provide comprehensive capital solutions. The second class consists of Highly Specialised, Sector-Focused Boutiques, whose influence stems from deep, qualitative domain expertise, thought leadership in niche technical sub-segments, and a practitioner-led approach to advisory services. Therefore, advisory leadership is defined by the strategic alignment between the advisor’s core competency, whether global scale or vertical specialisation and the complexity and specific needs of the client’s mandate. Current market dynamics underscore the intensifying requirement for specialised advice. Despite a broader global market recalibration, the European sector exhibited remarkable resilience in the first half of 2025 (H1 2025), recording an impressive 52% year-on-year increase in funding, reaching $3.4 Billion across 182 deals. This substantial capital infusion is fuelling M&A activity, which remains the primary and preferred exit path for investors. The dominant transaction themes are consolidation across the value chain, driven by the desire to create end-to-end platforms, and a marked increase in Private Equity (PE) and strategic trade interest. Strategic findings confirm the leadership position of highly specialised firms such as Nelson Advisors, which focuses intently on specialised, high-growth sub-sectors including Healthcare AI and Cybersecurity, often guiding early-stage companies through M&A exits. Simultaneously, strategic personnel movements at global institutions, notably the hiring of a physician to lead the EMEA Healthcare Investment Banking franchise at Goldman Sachs, signal an aggressive strategic intent by the Global Financial Powerhouses to capture large-cap mandates involving clinically validated technology platforms. This report provides a detailed assessment of these two advisory classes and the underlying market forces shaping their competitive dynamic. The European Digital Health M&A Market Context: Resilience and Consolidation This section examines the macro-environmental factors and fundamental transaction drivers that establish the robust demand for specialised M&A advisory services in the European Digital Health sector. Market Size, Growth Trajectory, and Resilience (2023–2028 Forecast) The Digital Health sector represents one of the fastest-growing segments globally, providing a solid foundation for sustained M&A activity. The global Digital Health market was valued at $170.2 Billion in 2023 and is projected to surge by a significant 62%, exceeding $275 Billion by 2028. This long-term growth trajectory ensures that M&A remains a viable and necessary mechanism for market participants seeking rapid scale and technological integration. The European ecosystem, in particular, has demonstrated exceptional vigor, defying a broader global slowdown in capital deployment. While global Digital Health funding experienced an 11% year-on-year decline, reflecting a wider market recalibration, Europe's performance was in stark contrast. The region achieved a substantial 52% year-on-year increase in H1 2025 funding, totalling $3.4 billion across 182 deals. This performance propelled Europe's share of global funding to a record 26% in the first half of the year, a strong divergence from the US market where funding fell to its lowest level in five years. This influx of capital and strategic confidence indicates a pivotal moment of maturation within the European ecosystem. The average deal size in Europe for H1 2025 reached $18.6 Million, representing a threefold increase (3.0x higher) compared to Q2 2024 figures. This substantial increase in average deal size reflects a crucial shift in investor preference: capital is increasingly being allocated to larger, "high-conviction investments" rather than small, speculative ventures. Companies within the region are accumulating sufficient clinical evidence and scale to warrant substantial investor confidence and higher valuations. This market maturity inherently strengthens the positioning of sophisticated financial advisors capable of handling complex valuations rooted in demonstrated clinical efficacy and measurable revenue potential, rather than relying solely on early-stage user metrics. It elevates the technical complexity of M&A mandates, moving them squarely into the domain of highly experienced investment banks and specialised corporate finance experts. Core M&A Drivers: Consolidation, PE Momentum and Digital Integration M&A activity is driven by fundamental structural deficiencies in traditional healthcare systems and a relentless pursuit of efficiency. Digital Health solutions are explicitly designed to alleviate pain points such as outdated operational systems, administrative burden, and high inefficiency costs plaguing traditional systems. The Strategic Imperative of Vertical Integration A core M&A driver is the ongoing race among participants to achieve comprehensive value chain integration. The market remains highly fragmented, making it primed for consolidation. Providers are looking to pursue acquisitions that strategically enhance digital capabilities, integrate tech-driven health services, and expand their patient networks. The overarching strategic goal is the establishment of an interconnected healthcare ecosystem and a seamless patient pathway. Incumbents are actively engaged in a "continuing race... to be the first truly end-to-end platform," housing various elements of digital healthcare under a single entity. This structural drive for consolidation is expected to continue as businesses aim to service more comprehensive segments of the patient journey. Because M&A in this environment is often a defensive or strategically essential move, not merely a financial transaction, advisors must possess advanced expertise not only in valuation metrics but also in complex post-acquisition integration strategies, particularly concerning regulatory compliance and disparate data system harmonisation. Advisors who understand the end-to-end patient care journey from initial telemedicine consultation to pharmacy fulfillment, for instance, offer superior strategic counsel. Private Equity and Strategic Trade Interest The potential scale and robust growth of Digital Health are increasingly familiar to institutional investors, resulting in a surge in Private Equity (PE) interest. The intersection of technology and healthcare remains a highly attractive sector for PE, offering strong growth potential. As smaller businesses achieve necessary scale, either organically or through sequential consolidation, the volume of sponsor-led mid-market deals is expected to increase significantly. This increasing institutional interest is also driven by consumer demand factors. For instance, in the UK, data indicates that 33% of people had to wait a week or more to see a General Practitioner (GP) in 2024, leading consumers to seek online consultations for time-saving benefits, cost-effectiveness, and general convenience.Furthermore, government involvement, such as increased partnerships between private companies and public services like the NHS (allowing patients to access GPs and nurses through video consultations and specialist referrals), further validates the sector for major investment. This combination of strong patient demand, government validation, and technological advancement ensures sustained M&A volume growth. Exit Dynamics: M&A as the Primary Pathway The primary mechanism for realizing investor returns in the European Digital Health sector is M&A, rather than public market offerings. M&A remains the dominant exit route, contrasted with the recorded activity of only one IPO and three SPACs in H1 2025. In the first half of 2025, 30 ventures either went public or were acquired, with 25 M&A transactions recorded. A critical trend within this environment is the dominance of venture-to-venture (V2V) transactions, which accounted for a substantial 75% of recorded acquisitions during H1 2025. This demonstrates a phase of active consolidation and strategic growth among venture-backed companies themselves, often fueled by new growth-stage capital flowing into the region. For companies under pressure due to a tighter venture capital funding environment and a less active initial public offering (IPO) market, pursuing strategic M&A exits sooner becomes a necessity. This duality creates parallel streams of demand: one for the large-scale financial structuring offered by Class I advisors, and another for the highly tailored exit strategy services provided by Class II specialised boutiques. Key Digital Health M&A Market Drivers and Transaction Trends (2024–2025) M&A Driver/Trend Strategic Observation Advisory Impact Value Chain Consolidation Drive for "end-to-end platforms" and interconnected healthcare ecosystems Increased demand for advisors specialising in bolt-on acquisitions and integration strategy. Increasing PE Interest PE firms seek scale and strong growth potential in digitised care management systems Higher volume of sponsor-led mid-market deals requiring specialised due diligence. Consumer Convenience Demand Patients demand online consultations and digitised services Advisory focus shifts towards providers demonstrating robust scalability and user adoption metrics. European Funding Resilience Significant funding injection in H1 2025 despite global slowdown Strong pipeline of well-capitalized targets, increasing transaction quality over volume. Defining Leadership: The Bimodal Advisory Structure The analysis confirms that designating a singular "leading advisor" in European Digital Health is insufficient. Advisory leadership must be qualified by the firm’s ability to address specific transaction requirements related to scale, complexity, and specific sector knowledge. Class I: The Global Financial Powerhouses (Bulge Bracket and Full-Service Banks) These institutions define their leadership through their capacity for global execution, deep capital structuring expertise, and extensive access to global financial and corporate markets. They are characterized by vast global reach, the ability to raise significant capital, and the experience necessary to structure complex, multi-jurisdictional M&A transactions, particularly for large strategic acquirers or high-value targets. Their core competitive strength lies in their sector finance depth and their ability to integrate large-scale M&A mandates with associated capital markets solutions. These firms manage competitive auction processes for highly mature, large-cap targets and advise on public market readiness, including IPOs. Class II: The Highly Specialised, Sector-Focused Boutiques In contrast, Class II firms achieve leadership through specialisation and qualitative depth. Their influence is not derived from M&A volume or value across all sectors, but rather from deep vertical specialisation and recognized thought leadership within their specific niche. These firms are distinguished by a strong focus on technically complex sub-segments (such as HealthTech, Healthcare AI, and Cybersecurity) and the delivery of advisory services built on direct practitioner experience. These specialists are essential for guiding early-stage companies toward strategic M&A exits and successfully navigating mid-market transactions (e.g., founder exits or PE bolt-ons) where the core value driver is proprietary technology or complex intellectual property that requires nuanced valuation. Strategic Segmentation of Leading European Digital Health M&A Advisors Advisor Class Example Firm Primary Strategic Value Target Deal Type Key Differentiator Global Financial Powerhouse Goldman Sachs, Jefferies Global execution, Capital structuring, High-volume access Multi-billion strategic mergers, complex financing, IPO readiness Depth of capital resources and cross-sector integration Specialised Boutique Nelson Advisors Deep sector expertise, Practitioner-led exit strategy Early-stage exits, highly technical sub-sector M&A (AI, Cyber) Unrivalled vertical specialisation and market thought leadership Mid-Market Specialist ConAlliance, Livingstone Partners Regional expertise, Transaction volume in specific deal sizes Private Equity bolt-ons, regional consolidation, founder exits Strong mid-market relationships and efficiency Profiles of Leading Advisory Firms: Class I (Global Financial Powerhouses) Class I advisors compete primarily for mandates involving the largest transaction values and the highest complexity, leveraging global resources and comprehensive financial product lines. Goldman Sachs (GS): Strategic Strength and Focused Leadership Goldman Sachs has clearly signaled its intensification of effort in the European healthcare and technology sector through key strategic personnel decisions. The firm announced the hiring of Philippe Gallone as Partner and Head of Healthcare Investment Banking in EMEA. Based in London, Gallone brings significant experience, joining the firm with 20 years of healthcare banking expertise. The appointment of Gallone, who holds a medical degree from the University of Lausanne and is a trained physician, is a calculated strategic move by the institution. It demonstrates recognition of the critical need to bridge traditional financial valuation methods with the complex requirements of clinical validation and regulatory understanding inherent in mature Digital Health platforms. Given that the European market is now prioritising large, high-conviction investments requiring evidence of impact, the ability to speak the language of medical professionals and regulatory bodies is a significant competitive advantage. This strategic hire positions Goldman Sachs to handle transactions where clinical data and regulated health systems are central to the target’s value proposition, directly challenging the deep sector knowledge historically claimed by specialized boutiques. The intent is to strengthen client relationships and drive growth across the EMEA healthcare franchise through a highly specialised lens. Jefferies: Full-Service Execution and Market Breadth Jefferies is recognised internationally as a leading full-service investment banking and capital markets firm. In the context of Digital Health M&A, Jefferies is a key competitor known for its robust execution capabilities across the capital stack. The firm targets mid- to large-cap healthcare mandates, offering clients a comprehensive partnership that includes insightful strategic advice, driven execution, and high-touch service. Its ability to seamlessly integrate M&A advice with capital raising, spanning equity, debt, and subsequent financing needs, is essential for funding complex, platform building acquisitions and managing the integration costs associated with large-scale consolidation. Full-Service Corporate Advisory: Alvarez & Marsal (A&M) Alvarez & Marsal (A&M) operates significantly in the corporate finance advisory space in Europe, specifically within the Digital Health M&A market. While a major portion of their corporate advisory work may focus on due diligence, performance improvement, and financial restructuring, functions crucial to transaction enablement and success, A&M is also actively monitoring and reporting on the Digital Health M&A market, noting the strong trends in consolidation and Private Equity interest. A&M fields a dedicated Healthcare and Life Sciences (HLS) M&A division in Europe. Key contacts leading this fully resourced team include Al-Munther Sultan (Managing Director and Head of HLS M&A), Claire Edwards (Director), and Rob Sher (Senior Associate). Their role is increasingly relevant as transaction volumes rise and the complexity of integration demands specialised expertise in financial and operational diligence post-transaction. Profiles of Leading Advisory Firms: Class II (Specialised Boutiques and Mid-Market Experts) The leadership of specialised boutique firms is derived from their unparalleled depth in vertical technology segments, often offering value propositions that global banks cannot easily replicate for mid-market or highly technical assets. Nelson Advisors: The Niche Dominator in European Digital Health Exits Nelson Advisors has carved out a distinct and qualitative leadership position by focusing exclusively on Healthcare Technology Mergers, Acquisitions, and Partnerships. The firm’s specialisation is comprehensive, covering MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, and, notably, Healthcare AI. Strategic Specialisation and Market Positioning Nelson Advisors’ strategic positioning is centred at the forefront of critical, high-growth sub-sectors such as Healthcare AI and Cybersecurity. This targeted focus is highly strategic, recognising that deep sector-specific expertise provides a critical competitive edge over sheer brand recognition in highly regulated and technically intricate niches. For companies developing highly proprietary technology, an advisor who is regarded as a thought leader in that specific vertical can better articulate the unique value proposition to potential strategic or financial buyers. The firm's focus on guiding early-stage companies through M&A exits is a calculated response to adverse market conditions, including a tighter venture capital funding environment and a relatively less active IPO market. This confirms a market demand for highly specialised services designed to maximise returns for high-potential, yet capital-constrained, ventures. Nelson Advisors: Specialisation Focus in European Digital Health M&A Specialised Sub-Sector M&A Implication & Client Focus Contextual Justification Digital Health / HealthTech Focus on mobile health, telehealth platforms, wearables, and personalised wellness solutions. Covers a broad range of technology-driven solutions. Healthcare AI Valuation of proprietary algorithms and data-driven clinical efficiencies; future M&A hotspot. Strategically positioned at the forefront of critical, high-growth sub-sectors. Healthcare Cybersecurity Focus on firms securing patient data and infrastructure, highly sensitive to EU regulation. Key focus responding to market conditions and regulatory demands. MedTech (Advanced Devices) Integration of traditional medical devices with software/digital solutions (robotics, bioprinting). Encompasses use of technology, products, and services to diagnose, prevent, monitor, treat. The Practitioner-Led Model Nelson Advisors is led by co-founders Lloyd Price and Paul Hemings, whose unique, practitioner-led advisory service is derived from their direct experience in both building and successfully exiting HealthTech businesses. This emphasis on practical, operational experience, rather than solely corporate finance expertise, suggests a strong market demand for advisors who fundamentally understand the operational leverage and strategic challenges faced by founders. This model likely leads to superior alignment between advisory goals and founder objectives, resulting in smoother and more strategically focused due diligence and valuation processes, a major advantage for PE firms executing strategic bolt-ons or corporate buyers seeking seamless technical integration. ConAlliance: Specialised Mid-Market Focus ConAlliance has established itself as a significant mid-market M&A advisor in European healthcare and life sciences. The firm maintains an exclusive focus on advising companies within the mid-market segment. With a robust track record of advising on more than 250 M&A transactions, ConAlliance demonstrates significant transactional volume and deep market connections in this specific segment. Their expertise spans critical areas including medical technology, pharmaceuticals, life sciences, biotechnology, medical devices, diagnostics, and laboratories, making them a crucial partner for founder-led exits and PE-backed consolidation strategies in the mid-range value band. Other Key Regional Players The market also relies on highly competent regional firms that deliver specialised, localised expertise. Livingstone Partners is actively engaged in the healthcare sector, with a focus on Medical Technology & Products and Outsourced & Tech-Enabled Services. Their recent involvement includes advising the shareholders of iPractice, an innovative mental healthcare provider in the Netherlands, on its sale to Smile Invest. This highlights the critical role regional specialists play in niche segments, such as mental health technology, and specific national markets (e.g., the Netherlands). The Ecosystem of Legal and Transaction Support The successful execution of complex Digital Health M&A mandates is rarely achieved by investment banks alone; it requires close coordination with elite legal counsel specialising in cross-border finance, technology law, and intricate health regulation. Firms like Taylor Wessing (with corporate technology partner Josef Fuss based in London) and Wilson Sonsini Goodrich & Rosati (WSGR) (whose team includes partners Megan Baier and Daniel Glazer) are confirmed as central players. These legal partners have advised major European Digital Health entities, such as Babylon Health, on large funding rounds and related acquisitions. This collaboration, exemplified by the partnership between Taylor Wessing and WSGR, is essential for navigating the complex regulatory environment of Europe, specifically addressing GDPR compliance, the evolving EU AI Act, and managing cross-jurisdictional licensing required for companies operating across multiple European markets (eg. the multi-market footprint of Kry/Livi, encompassing the UK, Sweden, Norway, and France). The strategic importance of legal advisors in mitigating regulatory risk elevates them to critical enablers in the European M&A ecosystem. Strategic Outlook and Actionable Recommendations Future M&A Hotspots: AI, Clinical Validation, and Productivity Premium The future direction of M&A activity will be dictated by technological sophistication and demonstrable return on investment. The prevailing investment sentiment indicates that capital deployment will be selective, demonstrating a strong preference for Artificial Intelligence (AI) ventures that have successfully converted clinical validation into tangible revenue streams. Furthermore, solutions that demonstrably offer a clear "productivity premium" through the streamlining of care pathways or the reduction of operational costs will continue to attract premium interest. This reinforces the ongoing trend of consolidation, as strategic buyers and PE firms seek accretive technologies that provide measurable cost-saving benefits and efficiency gains. This investor focus on clinically validated outcomes and productivity necessitates a fundamental shift in the valuation criteria applied to Digital Health targets. Advisors must possess the ability to quantify efficiency gains in clinical workflows and demonstrate robust regulatory compliance, moving beyond simple metrics like user adoption or subscription growth. The complexity of financial projections, which increasingly rely on clinical outcomes rather than just market penetration, elevates the specialised boutiques (Class II) focusing on Healthcare AI, while simultaneously requiring that global powerhouses (Class I) hire clinically sophisticated teams, as evidenced by the appointment of a physician to lead Goldman Sachs' EMEA Healthcare Investment Banking. Criteria for Advisor Selection: Tailoring Mandates The selection of an M&A advisor must be a highly tailored strategic decision, optimally aligning the firm's inherent competitive advantages with the client’s specific transaction objective. Selection of Global Powerhouses The Global Financial Powerhouses (Class I) are the optimal choice when: The transaction size is large-cap (exceeding $500 million) or requires the integration of significant debt, equity, or specialised capital markets solutions alongside the M&A execution. The mandate is multi-jurisdictional and involves complex integration with global incumbents in the pharmaceutical, technology, or insurance sectors. The client’s long-term strategy involves eventual public market access, requiring specialized pre-IPO positioning and underwriting capabilities. Selection of Specialised Boutiques The Highly Specialised Boutiques (Class II) are the optimal choice when: The target operates within a highly technical and nascent niche, such as early-stage AI, specialised MedTech integration, or Healthcare Cybersecurity. The transaction represents a strategic exit for founders who explicitly require an advisor with operational, practitioner-led experience derived from having previously built and exited similar HealthTech businesses. The transaction is a mid-market bolt-on acquisition where intimate sector knowledge is paramount for accurate valuation and smooth post-deal technical integration. Conclusions: The Strategic Imperative of Specialised Alignment The European Digital Health M&A advisory landscape is defined by its strategic bifurcation, reflecting the maturity of the ecosystem and the complexity of its underlying assets. Leadership is not monolithic; it is shared between the global reach of institutions capable of mobilising massive capital (Goldman Sachs, Jefferies) and the deep technical competence of highly specialised firms (Nelson Advisors, ConAlliance). The key takeaway for corporate development executives and PE partners is that transaction success increasingly depends on matching the specific nature of the asset being acquired, whether a scaling platform or a technical niche solution, with the appropriate advisory skillset. Given the high rate of V2V consolidation and the unrelenting drive for end-to-end platforms, technical due diligence and post-acquisition integration readiness, often facilitated by the deep operational insights of specialist advisors, become the primary determinants of transaction value capture. Failure to align the advisory team’s expertise with the specific regulatory and technical challenges of a Digital Health mandate poses a significant risk to deal execution and long-term integration success. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors invited to present to the MBA Students and Healthcare Club at the IESE Business School, Barcelona Nelson Advisors have accepted an invitation to present to the Healthcare Club at the IESE Business School, Barcelona in December 2025. The Founding Partners of Nelson Advisors believe strongly in sharing their experiences and knowledge of the HealthTech and MedTech markets with students across a wide range of UK and European Universities ranging from Oxford University and University of Cambridge to London Business School and University College London Global Business Schood for Health to IESE Business School. IESE Business School IESE Business School is the graduate business school of the University of Navarra, with its main campus located in Barcelona, Spain. It is consistently ranked among the top business schools globally, particularly for its MBA and Executive Education programs. Key Characteristics Global Mindset: IESE has a strong international focus with a highly diverse student body and campuses in Barcelona, Madrid, New York, Munich, and São Paulo. Case Method: The school is well-known for its extensive use of the case method, a teaching approach that uses real-world business problems to develop students' critical thinking, problem-solving, and decision-making skills. Values-Based Leadership: IESE emphasises a people centred vision and a commitment to ethics and social responsibility, aiming to educate leaders who can have a positive impact on business and society. Programmes IESE offers a variety of programs, including: Full-time MBA: A 15- or 19-month program known for its global approach. The curriculum includes core courses in the first year and a wide selection of electives in the second. Executive MBA (EMBA): A part-time program designed for experienced professionals. Global Executive MBA (GEMBA): A blended program with on-campus and online components. Executive Education Programs: These are consistently ranked among the best in the world and are aimed at functional managers, senior executives, and C-suite leaders. Rankings and Reputation IESE's programs are highly regarded in international rankings. Recent rankings include: Financial Times Global MBA Ranking: Consistently ranked in the top 10, with a #3 ranking in 2025. The Economist Full-time MBA Ranking: Ranked #1 in the world in 2021. Financial Times Executive Education: Ranked #1 for six consecutive years (2015-2020) and continues to be highly ranked. The school holds triple accreditation from AACSB, AMBA, and EQUIS. IESE Business School > Healthcare Club The IESE Business School Healthcare Club is a professional student club at IESE that focuses on the healthcare industry. Its mission is to support IESE students who are interested in pursuing a career in healthcare by providing them with the resources, knowledge, and networking opportunities they need. The club's activities are designed to help students: Learn about the healthcare sector: They organize seminars, workshops, and panels with industry experts, IESE professors, and alumni. These events cover various aspects of the healthcare industry, from pharmaceuticals and medical devices to digital health and healthcare consulting. Network with industry professionals: The club facilitates connections with leading healthcare companies, startups, and alumni. They host networking events, company visits, and an annual "Healthcare Day" conference, which brings together top professionals to discuss current trends and challenges in the industry. Find a job in the healthcare sector: The club offers career support through CV/cover letter workshops, interview preparation, and a mentorship program that connects students with experienced professionals. They also organize career treks to major healthcare hubs like Basel, Switzerland, and Madrid, Spain, where students can visit companies and network with potential employers. The IESE Healthcare Club plays a key role in positioning the IESE MBA as a source of top talent for healthcare companies and is a valuable resource for students aiming to transition into or advance their careers in this dynamic and impactful industry. Nelson Advisors > HealthTech and MedTech M&A Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish MedTech and Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views with MedTech and Healthcare Technology insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech founders advising HealthTech and MedTech founders.’ Nelson Advisors partner with entrepreneurs, chair persons, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #MedTech #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #DefenceTech #Nelson #Advisors Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT Contact Us lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us at MedTech and HealthTech industry events around the Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Global Health Exhibition 2025 > October 27th-30th 2025, Riyadh, Saudi Arabia HealthTechX 2025 > 4th November 2025, London, UK Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MedTech Malta 2025 > 12th-14th November 2025, Valetta, Malta MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers and acquisitions, partnerships and investments for MedTech, Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors Partner Lloyd Price has been invited to Judge the PitchFest Awards at ReWired 2026. This is the 3rd time Lloyd has Judged the prestigious awards, highlighting the pedigree of UK Digital Health and MedTech companies. PitchFest Awards at ReWired 2026 The PitchFest Awards at ReWired 2026 is the final stage of the UK's most high-profile digital health start-up competition, organised as part of the annual Digital Health Rewired conference and exhibition. It provides a platform for innovators to pitch their solutions to influential leaders, investors, and NHS digital teams. The competition follows a phased process to select the final winners: Application: Start-ups submit their proposals. The deadline for 2026 applications is 21 November 2025. Virtual Heats: Shortlisted contestants pitch their solutions virtually to a panel of judges from the NHS, venture capitalists, and digital health accelerators. Live Final: The top finalists compete live on stage at the Rewired conference. https://digitalhealthrewired.com Winner's Prize The winners receive significant support and exposure, most notably: Pilot Opportunity: Expert advice and the potential to run a real-world project within the Chelsea and Westminster Hospital NHS Foundation Trust, delivered through the CW Innovation Team and Pitchfest partner CW+. Visibility: Free entry to Rewired 2026 and features on Digital Health News. The competition often includes separate categories for pre-revenue and revenue-generating start-ups. Past winners have achieved significant growth and secured funding within the NHS and international markets. https://digitalhealthrewired.com/pitchfest Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

The Fragility of Progress: A Technical Deep Dive into Microsoft's Research paper, the "Illusion of Readiness" in Multimodal Health AI Benchmarking Executive Synopsis and Strategic Findings Critique Overview: The Disconnect between Leaderboard Metrics and Clinical Reliability The Microsoft Research paper, "The Illusion of Readiness: Stress Testing Large Frontier Models on Multimodal Medical Benchmarks", delivers a strategic and technical indictment of the current methodology used to evaluate Large Frontier Models (LFMs) in healthcare. The central conclusion is that high scores achieved by leading systems, such as GPT-5, on static medical benchmarks cultivate a misleading "illusion of readiness" for high-stakes clinical deployment. The researchers assert that this perceived progress is largely an artifact of evaluation methodologies that reward test-taking strategies rather than genuine, robust medical understanding. While conventional accuracy metrics suggest steady advancement, a granular, adversarial analysis reveals fundamental behavioural fragilities that are inconsistent with the demands of clinical trustworthiness. The authors caution that reliance solely on aggregated benchmark scores fundamentally misrepresents a model’s capacity for real-world reliability. Summary of Observed Failure Modes (Shortcut Learning, Brittleness, Fabricated Reasoning) Through a series of five targeted stress tests (T1-T5), the study exposed three primary categories of hidden vulnerabilities within leading multimodal LFMs: Shortcut Learning (Modality Exploitation): Models demonstrated the ability to correctly guess the answer even when critical inputs, such as the mandatory medical image, were removed. This signifies that the system bypasses genuine cross-modal understanding, relying instead on exploiting statistical patterns, textual priors, or memorisation embedded in the training data. Brittle Performance (Lack of Robustness): Systems exhibited profound instability under trivial or medically irrelevant perturbations. This fragility manifests as large shifts in predictions caused by actions such as reordering answer choices or making minor alterations to the prompt format. Such behaviour indicates poor foundational calibration and unreliability necessary for clinical decision support. Fabricated Reasoning (Unfaithful Explanations): A major technical concern is the frequent production of confident, medically sound rationales that are functionally disconnected from the actual process used to derive the final answer. Models often generated complex visual reasoning narratives to support a conclusion, even if that conclusion was derived from a textual shortcut, rendering the output logic actively deceptive for audit purposes. Strategic Recommendations for Evaluation Reform and Regulatory Policy The technical fragility documented mandates an immediate shift in evaluation paradigms for safety-critical health AI: First, the adoption of mandatory adversarial stress testing (T1-T5) is necessary, requiring vendors to report a quantified Robustness Score alongside conventional accuracy. This dual metric demands stability in addition to performance. Second, regulatory policy must transition its focus from merely requiring the provision of an explanation to mandating the fidelity and functional linkage of that explanation to the cross-modal inputs. Systems must be held accountable for exhibiting sound reasoning that is aligned with genuine medical demands. Contextualising the Health AI Credibility Crisis Introduction to Large Frontier Models (LFMs) in Healthcare Large Frontier Models, including systems like GPT-5 and Gemini 2.5 Pro, represent the cutting edge of artificial intelligence, offering the potential to revolutionise high-stakes medical fields such as diagnostics, documentation automation, and clinical knowledge retrieval. These systems are designed to integrate multiple modalities, textual case histories, lab results, and diagnostic imagery, to support clinical judgment. However, the application of these powerful, yet opaque, systems to high-stakes environments introduces unique risks. Real-world medical decisions are characterised by uncertainty, reliance on incomplete information, and often high pressure. When an LFM is deployed in a Clinical Decision Support (CDS) capacity, its performance must be invariant to noise and robust against ambiguity. The observed chasm between headline benchmark achievement and underlying fragility suggests that health AI currently suffers from a credibility problem, failing to meet the high standards of robustness required for safe clinical integration. The Institutional Context and Mandate for Trustworthiness The research paper’s unique significance stems from its institutional origin: a collaborative effort between Microsoft Research and Microsoft Health & Life Sciences. The extensive author list includes specialists in foundation models and biomedical AI, such as Yu Gu, the corresponding author and known developer of PubMedBERT and enterprise AI solutions,, as well as senior leaders like Eric Horvitz and Matt Lungren, Chief Scientific Officer for HLS. The participation of key figures and divisions within a leading frontier model developer transforms this critique into a strategic internal self-audit. By transparently stress-testing their own systems (including those as advanced as GPT-5), the organisation is effectively establishing a high internal technical standard for clinical readiness. This action signals a powerful institutional recognition that achieving trust and managing liability in the healthcare sector requires safety and trustworthiness to take precedence over raw technical performance.The proactive exposure of fundamental fragilities serves as a critical policy document defining the prerequisites for responsible deployment across the entire vendor landscape. The Scope of Evaluation: Models and Benchmarks Under Scrutiny The comprehensive evaluation targeted six flagship LFMs, including GPT-5, Gemini 2.5 Pro, GPT-4o, and DeepSeek-VL2. These models represent the current state-of-the-art in multimodal capabilities and are actively being considered for high-value applications. These models were tested across six widely recognised multimodal medical benchmarks: NEJM (New England Journal of Medicine), JAMA (Journal of the American Medical Association), VQA-RAD, PMC-VQA, OmniMedVQA, and MIMIC-CXR. The specific selection of models and benchmarks ensures that the findings are timely and directly relevant to the systems currently dominating performance rankings and shaping perceptions of readiness in the biomedical AI community. The Adversarial Evaluation Framework: Stress Tests (T1-T5) Defining Robustness and the Robustness Score Metric The foundation of the paper’s argument lies in the insufficiency of static accuracy metrics to predict safety in clinical environments. The proposed solution is a modular framework of adversarial stress tests designed to systematically target known vulnerabilities, such as spurious pattern dependence and neglect of critical visual input. The technical centerpiece of this framework is the Robustness Score. For each of the five tests (T1-T5), a normalised score ranging from $$ is computed, where higher values denote greater behavioural stability under adversarial perturbation. The Mean Robustness Score, obtained by averaging across the five tests, serves as a quantitative measure of reliability, providing a much-needed objective metric to counter the misleading simplicity of conventional accuracy scores. This score effectively operationalises the concept of clinical trustworthiness by demanding verifiable stability against real-world data imperfections. T1 & T2: Modality Necessity and the Quantification of Shortcut Learning T1: Modality Sensitivity The Modality Sensitivity test (T1) assesses whether a model’s accuracy degrades appropriately when the image input is systematically removed from multimodal questions. The study observed highly inconsistent accuracy drops across different benchmarks. For instance, the accuracy of GPT-5 dropped significantly (13.33 percentage points) on NEJM tasks upon image removal, suggesting some visual dependence. Conversely, other benchmarks, such as JAMA, exhibited minimal change in accuracy. This inconsistency immediately highlights that model performance on some "multimodal" tasks is achievable using only the textual context, exposing heterogeneity in benchmark requirements. T2: Modality Necessity and the Shortcut Learning Risk The Modality Necessity test (T2) provides the definitive quantification of Shortcut Learning Risk. This test focused on a strictly curated subset of 175 questions from NEJM where the correct answer was clinically dependent only on the visual input. Despite the mandatory nature of the image, leading models demonstrated success rates significantly above the expected 20% random chance baseline. For example, GPT-5 scored 37.71%, and Gemini 2.5 Pro scored 37.14%. This margin, the 17.71 percentage point difference between observed performance and random chance without the required image—is a direct technical measure of the system’s reliance on non-visual shortcut cues, such as statistical priors, textual co-occurrence patterns, or memorized associations within the dataset. The practical implication of this success is profound: the models are optimized to recognize patterns that correlate with the correct answer, irrespective of the presence or functional necessity of the critical visual evidence. In a clinical environment, this translates directly to providing a confident diagnostic error that is textually plausible but not visually substantiated. A critical behavioural distinction was observed with GPT-4o, which scored only 3.4% on the T2 test, characterized by a high frequency of refusing to provide an answer without the required visual input. This refusal behaviour, which minimises the confident hallucination seen in other models, constitutes a superior safety mechanism for clinical decision support. The lower score of GPT-4o, therefore, represents a desirable safety alignment. prioritising caution under uncertainty over guessing based on spurious correlations. T3 & T4: Assessing System Brittleness T3: Format Perturbation The Format Perturbation test (T3) was designed to quantify brittleness by introducing minor, non-semantic changes to the prompt structure, such as shuffling the order of multiple-choice answers or slightly altering the phrasing of the question. The resulting performance shifts demonstrated that models exhibit brittle behaviour, with substantial changes in prediction despite the core medical question remaining invariant. This instability is unacceptable in clinical workflows, which are inherently variable. A robust system must demonstrate invariance to trivial input alterations; the observed fragility indicates that the underlying decision logic is sensitive to superficial features rather than focusing exclusively on the content of the medical query. T4: Distractor Replacement The Distractor Replacement test (T4) probes the depth of understanding by replacing the incorrect answer choices (distractors) with alternatives that are statistically or medically more plausible. If model performance degrades significantly under this test, it confirms that the system was likely succeeding by eliminating easily identifiable non-answers rather than confirming the correct diagnosis through comprehensive insight. This reveals a lack of adversarial robustness, the optimisation strategy focused on avoiding obvious flaws in the training data rather than establishing a deep, resilient medical cognitive model. T5: Visual Substitution The Visual Substitution test (T5) evaluates model resilience against compromised visual data. In clinical practice, images may be corrupted, poorly compressed, or subject to subtle artifacts introduced during acquisition or transmission. T5 ensures that a trustworthy system maintains stable performance despite encountering these common data integrity issues. Failures in this test indicate a lack of necessary generalization and robustness in the visual processing component, highlighting a weakness that would lead to unpredictable results when deployed with real-world, imperfect clinical imaging data. The Microsoft Research paper, "The Illusion of Readiness: Stress Testing Large Frontier Models on Multimodal Medical Benchmarks" Analysis of Disguised Failures and Brittle Behaviour Shortcut Learning as a Pattern-Matching Strategy The stress testing framework reveals that the observed success of LFMs is often achieved for technically incorrect reasons: optimisation for pattern recall rather than requiring multimodal reasoning. By retaining accuracy when visual inputs are intentionally removed (T2), the systems demonstrate that they function as advanced correlation engines that leverage statistical associations between text and answer labels. This optimisation towards superficial patterns, rather than functional cross-modal integration, carries profound clinical risks. While high performance may be maintained on in-distribution benchmark tasks, the reliance on priors makes these systems highly susceptible to catastrophic failure when presented with out-of-distribution cases, noise, or scenarios where the text and image provide contradictory information. The finding that conventional scores (the "green line" of progress) continue to rise while robustness scores (the "red line" of brittleness) either stagnate or decline illustrates that the technical trajectory is optimised for misleading metrics rather than behavioral stability, creating fundamentally unsafe systems for clinical use. The Problem of Unfaithful Reasoning (The Hallucination Audit Trail) The issue of fabricated reasoning poses the most significant threat to regulatory compliance and clinical auditability. Models often generate confident, medically sound, step-by-step rationales, despite the fact that these rationales are functionally disconnected from the actual mechanism that produced the answer. This occurs when models, often tuned via Reinforcement Learning from Human Feedback (RLHF), optimise for the linguistic appearance of structured logic—the tokens that convey plausibility—rather than the functional integrity of the decision. The result is a dangerous Hallucination Audit Trail. A model might use a textual shortcut to arrive at a correct diagnosis (a T2 failure), and then retroactively generate an elaborate visual justification that is compelling but false, referencing image features it never actually processed or relied upon. Because explainability (XAI) is essential for clinicians to verify the logic before acting on a high-stakes recommendation, this deception nullifies the purpose of the audit trail. The structural appearance of reasoning often lacks any functional linkage to the final result, necessitating that the standard for explainability shift from mere presence to demonstrable fidelity. Comparison: Conventional Scores vs. Robustness Metrics The discrepancy between the two types of metrics confirms that technological advancement, as currently measured, is fundamentally flawed for safety-critical domains. Conventional metrics, which drive leaderboard rankings, reward an optimisation path that prioritises aggregate performance on static data. The stress test results, however, demonstrate that this optimisation simultaneously leads to increased brittleness when the system encounters real-world perturbations or incomplete data. The resulting heatmap generated by the stress tests effectively disrupts the established leaderboard. Models that appear superior based on conventional accuracy may exhibit unique, severe failure modes when stressed, which are obscured when performance is averaged into a single scalar score. This evidence strongly argues that the community must abandon scalar ranking in favor of a multi-dimensional assessment vector that incorporates verified stability metrics derived from adversarial testing. The Discrepancy Between Accuracy and Robustness (Conceptual) Metric Type Behaviour Measured Progress Trajectory Risk Assessment Conventional Accuracy Average performance on static, in-distribution test sets (Test-Taking Skill). High (The "Green Line" of Progress). Low predictive value for real-world uncertainty; rewards superficial success. Mean Robustness Score Stability under adversarial input and perturbation (Genuine Understanding). Stagnant or Decreasing (The "Red Line" of Brittleness). High correlation with clinical trustworthiness and deployment resilience. Critique of Existing Benchmarks and Evaluation Paradigms Benchmarking the Benchmarks: The Clinician-Guided Rubric The research advocates for a comprehensive evaluation of the evaluation tools themselves, a critique of the benchmarks. The authors emphasise that misinterpreting leaderboard success as real-world competence arises because the cognitive demands of different benchmarks are unknown or ignored. To rectify this, the paper introduces a structured, clinician-guided rubric to profile benchmarks based on two axes: their inherent visual dependency and their required inference complexity. This methodology shifts the validation process into the domain of medical expertise, ensuring that performance evaluation criteria reflect authentic clinical cognitive demands, rather than being limited to computational metrics. Analysis of Benchmark Heterogeneity Applying the rubric revealed significant heterogeneity among the six widely used multimodal benchmarks. For instance, NEJM tasks were determined to demand high levels of both reasoning complexity and genuine visual inference. Conversely, the JAMA benchmark was found to be predominantly text-solvable, meaning high accuracy could be achieved by correlating the text with the answer without requiring deep visual integration.Similarly, VQA-RAD and PMC-VQA were identified as visually dependent but required low inference complexity. The primary consequence of this unrecognised heterogeneity is that the benchmarks are improperly treated as interchangeable measures of medical readiness, masking distinct and critical failure modes. A system optimised to perform well on a text-solvable benchmark (JAMA) is fundamentally unprepared for a complex visual inference task (NEJM), leading to dangerous misalignment between demonstrated capability and deployment application. This proves that a single, aggregated accuracy score cannot capture the multidimensional nature of clinical competence. The Necessity of Functional Linkage and Visual Grounding The data from the T2 test confirms that current models often achieve a high correlation between the inputs and the correct output without achieving functional linkage, the necessary causal link that proves the visual evidence drove the decision. For health AI to be safe, evaluation must ensure that functional linkage is robustly verified. The system must confirm that the visual input caused the correct prediction, not merely coincided with it. The vast variance in visual necessity across existing benchmarks underscores why a generalized accuracy score is diagnostically meaningless and reinforces the need for explicit testing that proves appropriate visual grounding before a multimodal system is cleared for clinical use. Deployment Safety and Regulatory Accountability The Dangers of Deploying Fragile LFMs in Clinical Settings The integration of fragile LFMs exhibiting shortcut learning and brittleness into clinical decision support (CDS) poses immediate and severe risks, including increased potential for diagnostic error, misdiagnosis, and erosion of the necessary trust between providers and technology. The lack of behavioural stability means that the numerical performance improvements are deceptive. When operating under the high uncertainty and incomplete information common in real clinical environments, these systems are guaranteed to fail in unpredictable ways if their underlying logic relies on statistical priors that are easily perturbed or removed, as demonstrated by T2 and T3. Requirements for Earning Clinical Trust The path toward earning clinical trust requires that AI systems be held accountable not just for accuracy, but for verifiable robustness, the fidelity of their reasoning, and genuine alignment with dynamic medical demands. The paper argues that the technical discipline of adversarial stress testing must transition from an optional research step to a mandatory prerequisite for deployment authorisation. Systems must be required to demonstrate stability under the T1-T5 perturbations, ensuring that their performance is backed by resilient architecture rather than brittle optimisation. Policy Implications and Governance for High-Risk Health AI The findings of the "Illusion of Readiness" paper provide critical, tangible metrics for operationalizing abstract regulatory principles in high-risk domains. Regulatory frameworks, specifically the EU AI Act and FDA guidance, demand risk-based assessments, technical robustness, and transparency for high-impact healthcare systems. The T1-T5 Robustness Scores offer the technical proof necessary to quantify "technical robustness," a metric far more reliable than conventional accuracy. Moreover, the discovery of fabricated reasoning directly challenges the core regulatory requirement for explainability and auditability. The system's ability to manufacture plausible, yet false, rationales renders the audit trail useless for clinical verification and error correction. This requires regulators to shift their focus from demanding an explanation to demanding demonstrable fidelity of the reasoning process, ensuring that the logic is functionally linked to the multimodal input. The technical evidence provided by this study must inform governance, demanding adherence to stability standards before clinical integration is authorised. Mapping Technical Failures to Regulatory Imperatives Technical Failure Mode Stress Test Exposure Regulatory Principle Violated (e.g., EU AI Act/FDA) Clinical Risk Consequence Shortcut Learning (Textual Prior) T2: Modality Necessity Data Integrity & Clinical Validity Confident misdiagnosis in visually ambiguous or novel cases. Fabricated Reasoning Clinician-Guided Rubric (C) Transparency & Explainability (Auditability) Destruction of the clinical audit trail; inability for human experts to correct flaws. Brittle Performance T3: Format Perturbation Technical Robustness & Safety Unpredictable system failure in high-stakes, variable clinical workflows. Future Direction: Towards Dynamic and Clinician-Guided Evaluation The study concludes that the future of safe health AI necessitates a move toward dynamic evaluation methods and greater human involvement in the assessment process. Developers must implement safety mechanisms that favour caution, learning from the superior refusal behaviour demonstrated by GPT-4o when faced with insufficient visual evidence (T2). Ultimately, the AI community must pivot from optimising purely for high average accuracy to designing systems that are fundamentally resilient and capable of demonstrating sound, functionally linked multimodal reasoning under realistic, adversarial clinical pressure. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Foundational Regulatory Framework and Applicability The European Union Data Act (Regulation (EU) 2023/2854) represents a paradigm shift in the governance of machine-generated data within the European data economy. As a central pillar of the EU’s Digital Decade objectives, the Data Act’s primary goal is to foster competition and innovation by mitigating technical and contractual lock-ins that historically granted manufacturers exclusive control over the data generated by connected products. This mandate has profound implications for the global Health Technology (HealthTech) sector. The Data Act’s Context and Definitional Scope for HealthTech The regulation applies broadly across all sectors, specifically targeting data generated by "Connected Products" and "Related Services" placed on the EU market, irrespective of the data holder’s location (extraterritorial reach). Scope of Application: Connected Health Products: HealthTech is explicitly named within the scope of the Data Act, covering a vast range of devices and software. Connected products encompass any device or wearable that obtains, generates, or collects data concerning its use or environment and is capable of transmitting such data. Examples specifically enumerated include implantable medical devices (such as pacemakers), diagnostic tools (like continuous glucose monitoring (CGM) devices and MRI scanners), therapeutic aids (smart insulin pens, infusion pumps), lifestyle devices (fitness trackers, wellness wearables), and the associated software medical devices (SaMD) or applications defined as "Related Services". The extensive functional and territorial scope mandates that all global HealthTech manufacturers exporting to or operating within the EU must comply. Defining Key Actors: The Data Act establishes a clear hierarchy of rights centred on the user, who is defined as the natural or legal person that owns, rents, or leases the product or receives the service. In the HealthTech context, the user may be the individual patient (B2C) or the healthcare provider (HCP), hospital, or clinic (B2B). The "Data Holder" is typically the device manufacturer or service provider who controls the technical means of access to the data. The "Data Recipient" is the third party designated by the user to receive the data, which could be a competing maintenance firm, an independent researcher, or a new digital health platform. Regulatory Timeline and Key Milestones for HealthTech The Data Act came into force on January 11, 2024. However, the primary compliance obligations are staggered, requiring immediate action for legal teams and long-term planning for R&D departments. Core Provisions Application (September 12, 2025): The majority of the Data Act’s mandates, particularly Chapter II (user rights to access and share data) and Chapter IV (rules on unfair contractual terms), become applicable. This date marks the commencement of the legal and contractual obligations, compelling manufacturers to implement internal procedures for handling data requests and to re-paper contracts to meet new transparency requirements. Product Design Mandate (September 12, 2026): A distinct compliance challenge arises one year later, as new connected products and related services placed on the market must be designed and manufactured in a manner that facilitates easy, secure, and default data access, the so-called "design-by-default" principle. This distinction in the implementation schedule creates a tiered compliance risk: manufacturers must address immediate legal and contractual liabilities in 2025, while simultaneously initiating costly, long-lead-time adjustments to product R&D pipelines to meet the physical device requirements mandated for 2026. Cloud Switching Fee Removal (January 12, 2027): For HealthTech providers utilizing Software as a Service (SaaS) or Platform as a Service (PaaS) solutions, the Data Act removes switching charges, including data egress fees, making it significantly easier for users (HCPs or enterprises) to switch cloud service providers. Development of Model Contractual Terms (MCTs): The European Commission is obliged to publish recommended, non-binding Model Contractual Terms by September 2025, covering data access, use, and reasonable compensation. These terms will immediately become essential benchmarks for companies as they overhaul their legal documentation in preparation for the application date. Layered Regulatory Requirements in HealthTech The implementation of the Data Act must be understood within the broader context of EU data strategy. The regulation applies to both personal data and non-personal data. In HealthTech, this often results in a blended dataset where device usage metrics (non-personal data) are inherently linked to the patient’s health profile (personal data), necessitating a unified governance framework. The Data Act is particularly critical when considered alongside the European Health Data Space (EHDS). The Data Act’s core function is to empower the user with control over the raw data co-generated by the device. In contrast, the EHDS, which establishes a common framework for health data exchange and secondary use (eg, research and public health), focuses on the standardised exchange and governance of electronic health records. A comprehensive HealthTech data strategy cannot address one regulation without anticipating the requirements of the other, particularly regarding data standards and security protocols. The New Data Governance Model: User Empowerment and Mandated Access Chapter II of the Data Act establishes the core framework for Business-to-Consumer (B2C) and Business-to-Business (B2B) data sharing, fundamentally shifting data control from the manufacturer to the product user.This transition places significant new operational and technical burdens on data holders. Transparency and Pre-Contractual Disclosure Manufacturers are required to provide comprehensive transparency regarding data generation before a contract for a connected product or service is concluded. This disclosure, mandated by Article 3, must cover several mandatory information points. : The nature, volume, and scope of data the product is likely to generate, including whether it generates data continuously and in real-time. Clear instructions on how the user may access, retrieve, or erase that data. A description of whether the manufacturer intends to use the data itself or allow a third party to use it, and the specific purposes for such use. This immediate contractual mandate requires legal and commercial teams to undertake a rigorous and time-consuming review and re-papering of all consumer and business agreements to incorporate these transparency requirements ahead of the September 2025 application date. Operationalising User Access and Sharing The right of access (Article 4) is not a simple, static disclosure but an ongoing regulatory compliance burden that mandates infrastructural changes. Mandate for Free and Real-time Access: Data must be made available easily, securely, and, critically, "free of charge" to the user. For connected medical devices that generate continuous physiological metrics (eg. heart rate, glucose levels), the access obligation extends to providing data "continuously and in real-time," where technically feasible. This necessitates that internal data infrastructure must evolve from a passive IT system to an obligatory, high-availability, zero-cost service platform. Manufacturers must build technical interfaces and establish internal processes specifically to respond to, manage, and execute these real-time data access requests. Obligation to Share with Third Parties: The Data Act grants the user the right to designate a third-party Data Recipient to receive the data. This obligation to share is crucial for fostering competition and directly impacts the high-margin aftermarket service sector. Exclusive access to diagnostics and performance data traditionally created a strong competitive lock-in, enabling manufacturers to dominate repair and maintenance services. By mandating the transfer of this data, the Data Act neutralises this proprietary lock-in, forcing manufacturers to compete based on service quality, features, and price, rather than data monopoly. Limitations on Third-Party Use: To protect the data holder’s primary market investment, the third-party recipient is subject to strict limitations : the recipient cannot use the data to develop a product that directly competes with the product from which the data was generated. Furthermore, the recipient cannot use the data to derive insights regarding the manufacturer's economic situation, assets, or proprietary production methods. The data holder is strictly limited in tracking the third party, only allowed to retain information necessary for the security and execution of the access request. Complexity of Multi-Party Data Governance The definition of "User" in HealthTech introduces a significant legal and operational complexity, particularly in the B2B context. When a healthcare organisation (HCP or hospital) purchases a device, the organisation qualifies as the "user" with Data Act rights. However, the generated data is overwhelmingly personal health data belonging to the individual patient, who is the "data subject" under the GDPR. This results in a critical multi-party governance scenario: the manufacturer (Data Holder) must reconcile the commercial user’s right to access the data with the natural person’s fundamental privacy rights. The manufacturer, when processing a hospital's request for patient data, must ensure that the hospital has a valid legal basis under the GDPR for accessing and subsequently directing the transfer of that sensitive health data. This places the device manufacturer in a fiduciary position of accountability, requiring robust protocols to verify the lawfulness of the downstream data use before facilitating any transfer. Technical and Interoperability Obligations The Data Act’s technical mandates necessitate a deep overhaul of HealthTech product architecture, favouring standardised, secure and open data exchange mechanisms over proprietary interfaces. The "Design-by-Default" Imperative (Post-Sept 2026) Article 3 mandates that new products and related services placed on the market after September 12, 2026, must be engineered to provide data in a "comprehensive, structured, commonly used and machine-readable format". This regulatory requirement imposes extensive costs on R&D departments. Historically, HealthTech manufacturers relied on proprietary formats and interfaces for data security and commercial control. Achieving compliance demands the deep integration of data access mechanisms directly into the device’s design (hardware and software), making secure and easy accessibility a default feature. This design requirement presents an especially acute challenge for specialized devices, such as implantable or battery-dependent medical technologies (eg. pacemakers). The continuous, real-time data provision required by the Data Act necessitates increased on-device processing and transmission capability. For devices where battery longevity is directly tied to regulatory safety and patient well-being, implementing continuous streaming functionality could lead to premature battery depletion and necessitate significantly earlier device replacement, which introduces patient risk and potentially conflicts with core safety requirements mandated by the Medical Device Regulation (MDR). The technical implementation choices must, therefore, be treated as critical legal and safety risk assessments. Leveraging Health Data Interoperability Standards To satisfy the requirement for "structured, commonly used" data, HealthTech organisations must adopt recognised industry data standards. Relying on proprietary data formats will result in perpetual, costly compliance hurdles and limit the functionality of data sharing. The standard of choice, which is also foundational to the European Health Data Space (EHDS), is HL7 Fast Healthcare Interoperability Resources (FHIR). FHIR uses a modular resource approach built on modern web technologies, enabling seamless, secure, and rapid data exchange across disparate platforms. FHIR’s capability to handle patient-generated health data (PGHD), lab results, and other critical clinical data streams makes its adoption a strategic imperative for EU market participation. By structuring device data according to FHIR standards, a company ensures it can participate in Common European Data Spaces, effectively turning a compliance expense into a strategic asset that facilitates ecosystem partnerships and enhanced market positioning. Cloud and Data Processing Service Switching (Chapter VI) The provisions in Chapter VI significantly disrupt the competitive dynamics of cloud-based HealthTech service providers. The Data Act mandates measures to enable customers to switch between providers of data processing services (cloud, PaaS, SaaS) quickly, smoothly, and without data loss or functionality degradation. Providers must offer open interfaces and export data in commonly used and machine-readable formats, reinforcing the need for standards like FHIR. For HealthTech SaMD vendors, the cost and technical difficulty of moving large, complex datasets previously acted as a powerful financial and technical lock-in barrier for B2B customers. By eliminating egress fees and requiring easier switching, scheduled for removal from January 2027, the Data Act compels cloud-based services to compete primarily on the quality of their service, security and feature sets, accelerating the need for continuous innovation to maintain market share. Navigating the Regulatory Minefield: Conflicts and Hierarchy The Data Act is a horizontal regulation that must be successfully integrated into an already dense regulatory environment, particularly concerning fundamental rights (GDPR) and product safety (MDR/IVDR). The Primacy of GDPR and Personal Health Data The Data Act explicitly states it complements, and is without prejudice to, the GDPR; where personal data is involved, the GDPR prevails. Health data constitutes "special categories" of personal data, imposing stringent requirements on processing and transfer. The Data Act does not create a new legal basis for processing; manufacturers facilitating data access must ensure the transfer is supported by a valid legal basis under GDPR Article 6 (e.g., explicit consent, legal obligation). A critical area of conflict resolution concerns the imposition of fees for data access: Data Act Obligation: Data access for the user must be provided "free of charge". GDPR Provision: The GDPR states that a copy of personal data must be provided free of charge, though "further copies may be subject to a reasonable fee". Since HealthTech data sets are almost invariably blended (personal data mixed with technical non-personal data), attempting to levy a fee under the GDPR’s "further copies" clause for a data transfer mandated by the Data Act is functionally untenable and significantly raises regulatory exposure. The necessity of providing a seamless, free user experience for the blended data set dictates that manufacturers must budget to absorb all reasonable costs of compliance, effectively treating all access requests as free of charge. The functional differences between the rights established by the Data Act and the GDPR are summarised below, illustrating the need for unified data access procedures. Comparative Analysis: Data Act User Rights vs. GDPR Data Subject Rights Dimension Data Act (DA) User Right GDPR Data Subject Right (Art. 15, 20) Strategic Implication for HealthTech Data Scope Personal and Non-Personal (Usage, Technical, Industrial Data). Personal Data only (Data relating to an identifiable natural person). Requires comprehensive, unified data mapping and governance for blended data sets. Right Name Right of Access and Sharing. Right of Access (Art. 15) and Right to Portability (Art. 20). DA extends portability beyond previous GDPR constraints to mandated third-party sharing, including commercial entities. Data Provision Cost (to User) Must be "Free of Charge." Free of Charge (First copy); reasonable fee permitted for further/excessive copies. Data holders must functionally treat all reasonable requests as free to avoid regulatory conflict. Third-Party Sharing Mandated transfer to a designated third party (Data Recipient), including competitors. Mandated transfer only to the data subject or another controller (limited scope). Significant legal exposure; requires strict contractual safeguards with the recipient (Section VI). Intersection with MDR/IVDR: Device Safety and Compliance The Data Act creates significant tension with the regulatory framework governing device safety. The "design-by-default" requirements may force hardware or software modifications that could be classified as a "substantial change" under the MDR or IVDR. Substantial changes necessitate new conformity assessments and re-certification, leading to costly and lengthy delays in market deployment. The Safety and Security Exception: This conflict is mitigated by a critical regulatory relief valve: the data holder may refuse to share data if it can demonstrate that the transfer would undermine the "security requirements of the connected product," resulting in "serious adverse effects to the health, safety or security of people". This provision is vital for implantable and critical care devices where data extraction methods could compromise operational integrity (eg. risk of battery drain or exposure of cybersecurity vulnerabilities). Any refusal based on safety grounds must be justified in writing and communicated to the national competent authority. Data Minimisation vs. Data Availability: The competing requirements of the Data Act (maximum data availability) and the GDPR (data minimisation) also demand careful data strategy. The Data Act requires the sharing of comprehensive product data and relevant metadata. This dual mandate necessitates manufacturers implement robust data segregation layers: personal data must be retained only under strict GDPR necessity, while corresponding non-personal machine-generated data (usage, technical logs) must be retained and curated to fulfil Data Act user access requests, increasing overall storage and data management costs. Strategic Disruption and Business Model Re-engineering The Data Act enforces a structural devaluation of raw, exclusive data access, forcing HealthTech companies to abandon traditional proprietary business models in favour of new strategies based on data processing excellence, service quality, and derived intelligence. The End of Data Exclusivity and Aftermarket Lock-in The core consequence of the Data Act is the loss of competitive advantage derived from exclusive data control. Raw usage data, once considered an unassailable asset, must now be shared. As discussed, this directly enables rival aftermarket service providers to compete effectively on maintenance and repair contracts, thereby eroding the manufacturer's traditionally high-margin revenue streams from proprietary diagnostics and service agreements. Compensation Models for Third-Party Sharing For Business-to-Business (B2B) data sharing, the Data Act permits compensation when data is provided to a third-party Data Recipient (eg. a competing analytics firm). However, this compensation mechanism is strictly regulated. The FRAND Principle: Compensation must be non-discriminatory, reasonable, and adhere to Fair, Reasonable, and Non-Discriminatory (FRAND) terms. Limitation to Direct Costs: Crucially, compensation is limited to the direct technical and organisational costs incurred in making the data available, such as costs for formatting, electronic dissemination, and storage, plus a "reasonable margin". This structure explicitly prohibits data holders from recouping the significant upfront research and development investments related to the creation of the data or the device itself through licensing fees. The economic model shifts from monetising the value of the data to recovering the cost of its delivery. Developing New Value Propositions: From Raw Data to Derived Value Future profitability relies on leveraging proprietary expertise and sophisticated data synthesis techniques that create higher-margin derived value outside the scope of raw data sharing mandates. This requires a fundamental pivot in investment allocation, prioritising software and AI development over the traditional emphasis on hardware exclusivity. Focus on Derived Insights: HealthTech companies must shift their focus to selling advanced analytical services, curated aggregated data products, and sophisticated clinical decision support systems built on proprietary algorithms. While raw input and output data must be shared, the complexity and expertise required to generate meaningful clinical or operational insights from that raw stream can be monetised through high-value subscriptions. Strategic Differentiation through Data Quality: While raw data must be shared, the manufacturer retains control over the initial data quality, including sensor calibration, logging frequency, and metadata richness. This proprietary control over the source of the data offers a competitive advantage. Manufacturers can establish their superior data quality and curation capabilities as a specialised service, justifying premium pricing for analytics and data cleansing, making them the preferred partner even in a competitive landscape. The necessary strategic transition requires a comprehensive re-evaluation of revenue streams: Strategic Shift: Revenue Models and Competitive Risks Post-Data Act Current Model (Pre-DA) Impact of Data Act Mandatory Adaptation (Post-DA Strategy) Data Source (DA Status) Exclusive Licensing of Raw Usage Data (B2B) Mandated sharing limits revenue to delivery costs + margin (FRAND). Shift to licensing highly specialised, anonymised, aggregated data products and insights, which hold greater value and higher margins. Non-Personal Data (Directly Accessible) High-Margin Aftermarket Maintenance/Repair Users can direct device data to lower-cost third-party service providers. Focus on high-value predictive maintenance, exclusive calibration services, and extended warranties based on deep domain expertise and proprietary non-DA algorithms. Raw Usage Data (Shared) Cloud Lock-in and Egress Fees Switching is frictionless, and egress fees are prohibited (from 2027). Compete purely on platform security, technical superiority, and value-added SaaS features (e.g., enhanced analytics, dedicated clinical support workflows). Related Service Data (Highly portable) Mitigation Strategies: Protecting Intellectual Property and Trade Secrets The Data Act acknowledges the need to protect data holders' investments and includes explicit safeguards for intellectual property (IP) and trade secrets. A proactive, meticulous strategy is required to leverage these protections against the high risk of competitive disclosure. Identifying and Protecting Proprietary Assets Manufacturers must conduct a rigorous internal audit to identify and formally document all data, metadata, and proprietary algorithms that qualify as a trade secret (confidential, possessing commercial value, and subject to reasonable protection measures). The greatest vulnerability lies in proprietary algorithms, particularly those used for clinical processing, diagnostics, or sensor calibration. While the algorithm itself may be protected as a trade secret, the mandated sharing of large volumes of raw input data (from the sensor) and corresponding output data (the result) provides competitors with the foundational dataset necessary to reverse-engineer and train highly effective competing models, potentially circumventing contractual IP protections. Protection must extend beyond source code to the necessary data filtering mechanisms. Implementing Contractual and Technical Safeguards The Data Act permits the data holder and the third-party recipient to agree on proportionate technical and organisational measures (TOMs) necessary to preserve confidentiality. Contractual Measures: Standardised contracts for Data Recipients must be robustly developed, incorporating non-disclosure agreements, strict confidentiality clauses, and explicit prohibitions on competitive use and reverse engineering. The forthcoming Model Contractual Terms (MCTs) from the European Commission will provide a critical reference point for these agreements. Technical Protection Measures (TPMs): Reliance solely on contracts is insufficient given the digital nature of the data transfer. Data holders must deploy Technical Protection Measures, which may include secure, controlled access environments, mandatory authentication protocols, targeted data preprocessing (eg. redacting or aggregating highly sensitive metadata), digital watermarking, and information fingerprinting to track usage. Navigating Refusal and the Burden of Proof The Data Act allows a data holder to refuse access if these protective measures cannot be agreed upon or implemented by the third party. Furthermore, the data holder may refuse to share data if it can demonstrate that it is "highly likely to suffer serious economic damage" from the disclosure of trade secrets. This threshold is significantly demanding. Industry analysis suggests that the high burden of proof creates a substantial legal and administrative risk, potentially forcing disclosure if the justification is not meticulously documented. Any decision to withhold or suspend data sharing must be justified in writing and formally communicated to the national competent authority. This introduces a novel administrative enforcement risk; unlike traditional IP disputes that are purely civil, a Data Act refusal immediately subjects the manufacturer to regulatory scrutiny, requiring legal and technical teams to prepare standardised, highly defensible justification templates in advance. Comprehensive Strategic Compliance Roadmap Compliance with the Data Act is not merely a legal exercise but a strategic imperative that requires deep, cross-functional organizational re-engineering across R&D, IT, Legal, and Commercial departments. Phase 1: Regulatory Impact Assessment and Data Mapping (Immediate Action) The initial phase must prioritise understanding the scope of liability and preparing the necessary legal infrastructure before September 2025. Data Inventory and Classification: A comprehensive audit of all data generated by connected products and services must be performed. This data must be meticulously categorised, distinguishing between sharable non-personal data (Data Act scope), sensitive personal health data (GDPR scope), and proprietary trade secrets/IP. Legal and Operational Gap Analysis: Current IT infrastructure, data storage formats, and existing contractual terms must be assessed against the Data Act's requirements (e.g., real-time accessibility, FHIR standards alignment). Any potential compliance friction points with the MDR/IVDR, particularly where design changes could trigger re-certification, must be identified and documented. Governance Establishment: A dedicated, cross-functional Data Act compliance committee involving legal counsel, the Data Protection Officer, R&D leadership, and commercial strategy directors must be established to define clear internal accountability and data handling procedures. Phase 2: Product Design and IT Infrastructure Overhaul (2025 – 2026) This phase focuses on technical readiness, particularly for products launching post-September 2026. Interoperability and API Development: Manufacturers must prioritise R&D investment in building robust, secure, and standardised interfaces (preferably FHIR-based APIs) to facilitate continuous, real-time data access. This effort should aim for maximum interoperability to position the company favourably within the emerging European data ecosystem. Trade Secret Separation: Technical infrastructure must be architected to enable the efficient separation of sharable data from proprietary algorithms and trade secrets. This involves integrating Technical Protection Measures (TPMs). such as secure processing environments and data masking—into the sharing workflow to comply with Article 79 protective requirements. Scalable Data Platform: IT infrastructure must be upgraded to a scalable, cloud-native platform capable of securely managing high volumes of zero-cost data access requests while ensuring full compliance with both GDPR and Data Act security protocols. Phase 3: Contractual Review and Commercial Policy (2025 – 2026) Legal teams must manage the extensive re-papering process required ahead of the 2025 application date. Comprehensive Contract Updates: All B2C and B2B contracts must be updated to include the mandatory pre-contractual transparency information required by Article 3. Third-Party Data Sharing Agreements: Standardised contracts for third-party Data Recipients must be developed. These agreements must be meticulously drafted to include: (a) Explicit prohibitions on competitive development and trade secret use; (b) Clauses requiring the recipient to implement agreed-upon TPMs; and (c) Pricing based strictly on FRAND terms limited to direct delivery costs. GDPR Compliance Verification: A formal process must be implemented to verify that a third party requesting patient data has a valid GDPR legal basis (eg. explicit patient consent) for processing the sensitive health data, thereby mitigating the manufacturer’s residual GDPR liability. Conclusion The EU Data Act represents one of the most significant regulatory interventions in the digital health economy, structurally demanding a shift from proprietary data control to user empowerment and mandated sharing. For HealthTech companies, the Act eliminates key traditional barriers to entry for competitors, particularly those operating in the lucrative aftermarket services sector, and devalues raw data as an exclusive asset. Successful navigation of this transformative period requires treating compliance as a catalyst for innovation rather than solely a regulatory burden. Companies must strategically pivot their revenue models away from data exclusivity and toward the sophisticated monetisation of derived insights, specialised algorithms, and superior, high-quality service offerings. By proactively adopting interoperability standards (like FHIR), investing in secure, scalable data access infrastructure, and establishing rigorous legal frameworks to protect trade secrets and reconcile conflicting GDPR and MDR mandates, global HealthTech firms can secure market access and competitive positioning in the emerging European data economy. Delaying implementation efforts beyond the immediate need to update contractual terms (September 2025) and initiate R&D overhauls for new products (September 2026) will result in insurmountable compliance debt and commercial vulnerability. Nelson Advisors > MedTech and HealthTech M&A Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Us @ HealthTech events Digital Health Rewired > 18-19th March 2025 > Birmingham, UK NHS ConfedExpo > 11-12th June 2025 > Manchester, UK HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands Barclays Health Elevate > 25th June 2025, London, UK HIMSS AI in Healthcare > 10-11th July 2025, New York, USA Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany World Health Summit 2025 > October 12-14th 2025, Berlin, Germany HealthInvestor Healthcare Summit > October 16th 2025, London, UK HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany Venture Capital World Summit > 2nd December 2025, Toronto, Canada Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk